 
Original Application for an 
Investigational Device Exemption 
 
25 August 2020  
 
PIVOTAL STUDY  
OF SUBCUTANEOUS TIBIAL NERVE 
STIMULATION WITH eCoin® 
FOR  
URGENCY URINARY INCONTINENCE  
 
Device  Name:  eCoin® (Electroceutical Coin) 
IDE Number:   G170301  
 
Sponsor  & Manufacturer:  Valencia Technologies  Corporation  
28464 Westinghouse Place  
Valencia, CA 91355 
United States  
 
Principal Investigators:  See Attachment  4-25 
 
 
 
CONFIDENTIAL  
Document Number 111-3281 Rev 3 .9 
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 2 of 97   
  
TABLE OF CONTENTS  
1 INTRODUCTION  .................................................................................................................................................. 5 
NAME, ADDRESS , AND SIGNATURE  OF SPONSOR  ................................................................................................................................ 5 
OVERVIEW  ............................................................................................................................................................................................................... 5 
2 REPORT OF PRIOR INVESTIGATIONS  ......................................................................................................... 7 
PRIOR PUBLICATIONS OF  ANIMAL  STUDIES  .......................................................................................................................................... 7 
HUMAN  STUDIES  .................................................................................................................................................................................................. 8 
2-2-1 Prior Publications of Tibial Nerve Stimulation for  Overactive  Bladder  ......................................... 8 
2-2-2 Prior Studies of the Valencia Technologies  eCoinTM System  ............................................................... 9 
EXECUTIVE SUMMARY OF  NON-CLINICAL  STUDIES  ...................................................................................................................... 12 
2-3-1 Bench Testing -  eCoinTM Device  ................................................................................................................... 12 
2-3-2 Bench Testing  External  Controller  ............................................................................................................. 16 
2-3-3 MR Compatibility  .............................................................................................................................................. 17 
2-3-4 Electrical Safety and  Electromagnetic Compatibility ......................................................................... 17 
2-3-5 Electrical Safety and EMC  External  Controller  ..................................................................................... 19 
2-3-6 Software eCoinTM  Device (209 -1035,  209- 1061, 303- 1122)  ............................................................ 19 
2-3-7 Software External Controller  (207- 1541, 303- 1122)  ......................................................................... 19 
2-3-8 Biocompatibility  ................................................................................................................................................ 20 
2-3-9 Particulate (Nelson Lab  Number  884283- 01) ....................................................................................... 22 
2-3-10 Sterility (200 2-1206)  .................................................................................................................................... 22 
2-3-11 Packaging (202- 1254;  Westpak  225- 15-0053A)  ............................................................................... 22 
2-3-12 Shelf Life (202 -1254; Westpak  225- 15-0053B,  225- 15-0053C)  ................................................... 23 
3 INVESTIGATIONAL  PLAN  .............................................................................................................................. 24 
PURPOSE  .............................................................................................................................................................................................................. 24 
SUMMARY  ............................................................................................................................................................................................................ 24 
PROTOCOL  ........................................................................................................................................................................................................... 25 
3-3-1 Study Design ........................................................................................................................................................ 25 
3-3-2 Subject  Selection ................................................................................................................................................ 25 
3-3-3 Ethical  Considerations  .................................................................................................................................... 27 
STUDY  PROCEDURES  ...................................................................................................................................................................................... 28 
3-4-1 Recruitment  Plans  ............................................................................................................................................ 28 
3-4-2 Visit  Overview  ..................................................................................................................................................... 29 
3-4-3 Screening for  Eligibility  Procedures  .......................................................................................................... 32 
3-4-4 Prior and  Concomitant Therapy  ................................................................................................................. 32 
3-4-5 Informed  Consent Procedures  ...................................................................................................................... 32 
3-4-6 Baseline  Visit  Assessments  ............................................................................................................................. 32 
3-4-7 TENS  Protocol  .................................................................................................................................................... 33 
3-4-8 Implantation of Subcutaneous  Neuromodulation  System  ................................................................ 33 
3-4-9 eCoinTM Activation  ............................................................................................................................................ 33 
3-4-10 Establishment of the Amplitude  Setting  ................................................................................................ 33 
3-4-11 Post Activation  Follow -up Procedure  ..................................................................................................... 34 
3-4-12 Escape  Procedure  ........................................................................................................................................... 34 
STUDY  OBJECTIVES  ......................................................................................................................................................................................... 34 
3-5-1 Primary and Key  Secondary  Objectives  .................................................................................................... 34 
3-5-2 Secondary  Objectives  ....................................................................................................................................... 35 
RATIONALE FOR THE SELECTION OF OUTCOME MEASURES AND  STUDY  DESIGN  ......................................................... 35 
RISK ANALYSIS  .................................................................................................................................................................................................. 36 
3-7-1 Overview  ............................................................................................................................................................... 36 

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 3 of 97   
 3-7-2 Description of  Patient Population  .............................................................................................................. 37 
3-7-3 Justification  for Investigation  ...................................................................................................................... 38 
3-7-4 Additional Safety  Profile  Information  ...................................................................................................... 38 
3-7-5 Standards Conformance Demonstrating  Safety  ................................................................................... 40 
DESCRIPTION OF  THE  DEVICE  ................................................................................................................................................................... 41 
3-8-1 Components  ......................................................................................................................................................... 42 
3-8-2 Stimulation  Settings/Parameters  .............................................................................................................. 42 
3-8-3 Implant  Procedure  ............................................................................................................................................ 42 
3-8-4 Activation of  eCoinTM System  ........................................................................................................................ 43 
3-8-5 Subject  Compliance  Monitoring  .................................................................................................................. 43 
3-8-6 Safety and  Adverse  Events  ............................................................................................................................. 44 
3-8-7 Subject Withdrawal  & Termination  .......................................................................................................... 46 
3-8-8 Data and Safety  Monitoring Board  ............................................................................................................ 47 
DATA ANALYSIS PLAN  .................................................................................................................................................................................. 48 
3-9-1 Data Collection  ................................................................................................................................................... 48 
3-9-2 Interim  Monitoring  .......................................................................................................................................... 48 
3-9-3 Analysis  Plan  Summary  .................................................................................................................................. 49 
3-9-4 Sample  Size Consideration  ............................................................................................................................ 52 
3-9-5 Calculation of  Effectiveness Variables  ...................................................................................................... 53 
3-9-6 Missing  Outcome  Data .................................................................................................................................... 54 
3-9-7 Additional OAB medications  ......................................................................................................................... 54 
3-9-8 Safety  Analysis .................................................................................................................................................... 55 
DATA HANDLING , RECORD KEEPING AND  STUDY MONITORING  ........................................................................................ 57 
3-10-1 Confidentiality and  Security  ....................................................................................................................... 57 
3-10-2 Training  ............................................................................................................................................................. 57 
3-10-3 Documentation, Case Report Forms and  Source Documents  ........................................................ 57 
3-10-4 Device Accountability  ................................................................................................................................... 58 
3-10-5 Monitoring Procedures, Auditing, and Inspecting ............................................................................. 58 
3-10-6 Protocol Deviations  and Compliance  ...................................................................................................... 59 
METHODS , FACILITIES , AND  CONTROL INFORMATION  ............................................................................................................. 60 
3-11-1 Device Manufacturer  .................................................................................................................................... 60 
3-11-2 Organization and  Participating  Center  .................................................................................................  61 
3-11-3 Funding Source and Conflicts  of Interest  .............................................................................................. 61 
3-11-4 Institutional Review Board / Ethics  Committees  ............................................................................... 61 
3-11-5 Roles  and Responsibilities  ........................................................................................................................... 62 
3-11-6 Subject  Compensation  .................................................................................................................................. 63 
STUDY  TIMETABLE  ...................................................................................................................................................................................... 63 
4 ATTACHMENTS  ................................................................................................................................................ 64 
3-DAY  VOIDING  DIARY  ................................................................................................................................................................................. 65 
MANUALS , AND LABELS  ............................................................................................................................................................................... 66 
INVESTIGATOR ’S BROCHURE  ..................................................................................................................................................................... 67 
PATIENT TRIAL BROCHURE  AND  ADVERTISEMENT  ...................................................................................................................... 68 
INFORMED  CONSENT  DOCUMENT  ........................................................................................................................................................... 69 
PATIENT GLOBAL IMPRESSION  OF IMPROVEMENT  ........................................................................................................................ 70 
PATIENT IMPLANTATION  CARD  ............................................................................................................................................................... 71 
CASE  REPORT  FORMS  .................................................................................................................................................................................... 72 
ADVERSE EVENT  FORM ................................................................................................................................................................................ 73 
DSMB  CHARTER  .......................................................................................................................................................................................... 74 
OUS S TUDY FOR  HYPERTENSION  PROTOCOL  ............................................................................................................................... 75 
OUS S TUDY FOR HYPERTENSION CRF S FOR  INFECTIONS  ..................................................................................................... 76 
OUS S TUDY FOR HYPERTENSION DSMB L ETTER RECOMMENDING SUSPENSION OF IMPLANTATION AT  
SITE 12 77  
SNS R ISK ASSESSMENT  (110 -1493)  ..................................................................................................................... 78 

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 4 of 97   
 SUMMARY OF RISKS  AND  MITIGATIONS  ........................................................................................................................................... 79 
DESIGN VERIFICATION AND  VALIDATION  REPORTS  .................................................................................................................. 80 
ETHYLENE OXIDE STERILIZATION VALIDATION  REPORTS  .................................................................................................... 81 
STERILE PACKAGING VALIDATION  REPORT ................................................................................................................................... 82 
ENGINEERING  DRAWINGS  ........................................................................................................................................................................ 83 
ECOINTM DEVICE  MATERIALS ................................................................................................................................................................ 84 
TEMPLATE INVESTIGATOR  AGREEMENT  ......................................................................................................................................... 85 
CLINICAL MONITORING PLAN  ............................................................................................................................................................... 86 
ASSEMBLY PROCEDURE  ECOINTM DEVICE  ...................................................................................................................................... 87 
ASSEMBLY PROCEDURE STERILIZATION AND PACKAGING CLINICAL  MONITORING  PLAN  .................................... 88 
LIST OF INVESTIGATORS , CV S, AND CENTERS  ............................................................................................................................... 89 
303 -1122 S OFTWARE DESIGN  SPECIFICATION  SNS  ........................................................................................... 90 
BIOCOMPATIBILITY  REPORTS  ................................................................................................................................................................ 91 
BACTERIAL ENDOTOXINS  TEST  METHOD  ....................................................................................................................................... 92 
BIOBURDEN LEVELS AND RAW DATA  ............................................................................................................................................... 93 
BATTERY RECEIVING  INSPECTION  INSTRUCTIONS  ..................................................................................................................... 94 
REFERENCES  ................................................................................................................................................................................................... 95 
ECOINTM FOR OAB  FEASIBILITY : SAFETY  ....................................................................................................................................... 96 
4-32-1 Adverse Event Table  ...................................................................................................................................... 96 
4-32-2 Subject 01 -10 One Month Follow -up Implant  Site Picture  ............................................................. 96 
4-32-3 Subject 07 -17 AE  report  ............................................................................................................................... 96 
ECOINTM FOR OAB F EASIBILITY  STUDY PROTOCOL  .................................................................................................................. 97 

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 5 of 97   
  
 
 
Name, Address, and Signature of Sponsor  
 
Name:  Stacy  Chambliss  
 
Title:  Chief of Scientific  Review 
 
Address:  Valencia Technologies Corporation 
28464 Westinghouse Place  
Valencia, CA 91355 
United States  
 
 
Phone: +1 (661) 775 -1414 ext. 1002  
 
Fax: +1 (661) 775- 1411  
 
Email: schambliss@valenciatechnologies.com  
 
 
Signature  of Sponsor:   Date:     
 
Overview  
Overactive bladder (OAB) is a clinical diagnosis characterized by the presence of 
bothersome urinary symptoms including urgency, frequency, nocturia, and urgency 
incontinence. Urinary incontinence is a prevalent condition that markedly impacts quality 
of life affecting both men and women (1). In population- based studies, the prevalence of 
OAB ranges from 7% to 27% in men, and 9% to 43% in women (2- 9). Urgency urinary 
incontinence (UUI), which affects approximately one- third of patients with OAB, is 
associat ed with substantial negative effects on quality of life (HRQOL) (7). The 
unpredictable loss of urine and associated odor or related symptoms leads to well documented burden on quality of life. This study will focus on urgency urinary 
incontinence.  
 
While p hysical therapy and surgery are relatively effective treatments for stress urinary 
incontinence, disorders of the detrusor muscle and/or neural regulation of the lower 
urinary tract system remain quite challenging to treat well. A number of treatments, 
including first line behavioral therapies and second line medications (anti -muscarinics or 
oral β
3-adrenoceptor agonists), are available; however, many patients remain in poor 
control. For those not well treated by behavioral therapy or medications, or intolerant of 
medications, percutaneous tibial nerve stimulation (PTNS) as well as sacral nerve stimulation (SNS) are approved for marketing by the National Institute for Health and 
Clinical Excellence (NICE) in the United Kingdom and by the Food and Drug 
Admini stration in the United States. For PTNS, given the need for maintenance therapy 
over the long- term (10), the expense of such maintenance visits and waning efficacy of 
the therapy when conducted in the home (11), the use of a tiny fully -implantable device  
1 Introduction  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 6 of 97   
  
is likely to have advantages in implementation. Such advantages may include 
automated compliance, lower cost over device life compared with long- term visit costs, 
and improved efficacy through accurate device placement compared with percutaneous administration at home.  
1. Burgio KL, Locher JL, Goode PS, et al. Behavioral vs drug treatment for 
urge urinary  incontinence in older women: a randomized controlled trial. 
Jama  1998;280:1995- 2000.  
2. Choo MS, Ku JH, Lee JB et al: Cross -cultural differences  for adapting 
overactive bladder symptoms: results of an epidemiologic survey in Korea. 
World J Uro 2007; 25:  505. 
3. Corcos  J and Schick E: Prevalence of overactive bladder and incontinence 
in Canada. Can J Urol 2004; 11 : 2278.  
4. Coyne KS, Sexton CC, Vats V et al: National community prevalence of 
overactive bladder in the United States stratified by sex and age. Urology 
2011; 77: 1081.  
5. Tikkinen, KA, Auvinen A, Tiitinen A. et al: Reproductive factors associated 
with nocturia and urinary urgency inin women: A population- based study in 
Finland. Am J Obstet Gynecol 2008: 199: 153 e1. 
6. Irwin DE, Milsom I, Hunskaar  S et al: Population -based survey of urinary 
incontinence, overactive bladder, and other lower urinary tract symptoms  in 
five countries: Results of the EPIC study. Eur Urol 2006; 50 : 1306.  
7. Stewart WF, Van Rooyen JB, Cundiff GW et al: Prevalence and burden of 
overactive bladder in the United States. World J Uro 2003; 20:  327. 
8. Herschorn S, Gajewski J, Schulz J, et al: A population- based study of 
urinary symptoms and incontinence: The Canadian Urinary Bladder Survery. 
BJU Int 2008; 101 ; 52. 
9. Milsom I, Abrams P,  Cardozo L et al: How widespread are the symptoms of 
an overactive bladder and how are they managed? A population- based 
prevalence study. BJU Intl 2001; 87:  760. 
10. Yoong, Wai, et al. "Neuromodulative treatment with percutaneous tibial  nerve 
stimulation for i ntractable detrusor instability: outcomes following a shortened 6‐ 
week protocol." BJU international 106.11 (2010): 1673- 1676.  
11. van der Pal F, van Balken MR, Heesakkers  JP, et al: Percutaneous tibial 
nerve stimulation in the treatment of refractory overactive bladder syndrome: 
is maintenance treatment necessary? BJU Int 2006,  97(3):547– 550. 
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 7 of 97   
  
 
 
Prior Publications of Animal Studies  
The underlying science in support of tibial nerve stimulation for treatment of overactive 
bladder including urgency urinary incontinence has been well described in published 
scientific literature. For example, in 1966, McPher son demonstrated in a cat model that 
stimulation of the cut ends of dorsal spinal roots or various peripheral nerves including 
the posterior tibial nerve can effectively inhibit bladder contractions ( 12). The hypothesis 
for th is effect was an action of neural circuitry in the forebrain, as intercollicular 
decerebration or thoracic spinal cord transection abolished the effect ( 13). In 1980, Sato 
et al. verified that electrical stimulation of afferen t nerves to hind limb muscles, but not 
cutaneous afferents, inhibited reflex bladder activity in the anesthetized cat ( 14). Three 
years later, McGuire and Morrissey used electrical stimulation of the hindquarter nerves 
to trea t detrusor instability in spinal injured nonhuman primates before moving on to 
demonstrate a similar effect in the clinical setting in 16 patients ( 15). Case studies on 
percutaneous tibial nerve stimulation (PTNS) for overacti ve bladder were then 
conducted followed by several randomized, controlled trials.  
 
The tibial nerve is a mixed nerve comprised of sensory and motor nerve fibers. It is by 
action of central afferent fibers that neuromodulation of the tibial nerve works to r estore 
normal control of an imbalanced voiding reflex. The large diameter somatic afferent fibers of the tibial nerve cause inhibition of bladder activity by way of central inhibition of 
the micturition reflex pathway in the spinal cord or the brain. This action is confirmed by 
studies in anaesthetized female cats ( 14). Neuromodulation of the tibial nerve is 
presumed to improve or restore normal control of an imbalanced voiding reflex by action of the central afferents ( 12, 17). Thus, the therapy aims to cause detrusor inhibition by 
acute electrical stimulation of afferent tibial nerve fibers. Interestingly, the same spinal 
roots (L4 -S3) appear to be targeted by both sacral nerve stimulation and tibial nerve 
stimulation. It appears that stimulation of the sacral roots, sacral nerve, pudendal nerve 
and tibial nerve all affect central components of the neural circuits controlling the 
bladder, yet we can deduce some distinc tions in the action. Tai et al. showed that short 
duration stimulation of the tibial nerve causes a persistent post -stimulation inhibition and 
increase of bladder capacity ( 18) that is replicated by many tibial nerve clinical studies, 
yet the effects of sacral nerve stimulation are shown to go away once stimulation is 
stopped ( 19). 
 
As the bladder is controlled by sympathetic, parasympathetic, and somatic nervous 
systems that are regulated by the pontine micturition center (PMC), tibial nerve 
stimulation is likely to act on the PMC, either via the pelvic nerve or pudendal nerve or 
both. The pelvic nerve (S2- S4) controls bladder contraction (micturition) while the 
hypogastric (T10 -L2) and pudendal (L4 -S3) nerves control continence; stimulation of the 
large somatic afferent fibers of the tibial nerve, with spinal roots from L4 -S3, is 
postulated to finds its effect on the bladder via either the pelvic or the pudendal nerve.  
12. McPherson A. The effects of s omatic stimuli on the bladder in the cat. J  Physiol. 
1966;185(1):185– 96. 
13. McPherson A. Vesico- somatic reflexes in the chronic spinal cat. J  Physiol. 
1966;185(1):197– 204.PubMed  
2 Report of Prior  Investigations  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 8 of 97   
  
14. Sato A, Sato Y, Schmidt RF, Torigata Y. Somato -vesical reflexes in chronic 
spinal cats. J Auton Nerv Sy st. 1983;7:351– 62.PubMedCrossRef  
15. McGuire EJ, Zhang SC, Hor winski ER, Lytton B. Treatment of motor and sensory 
detrusor instability by electrical stimulation. J Urol.  1983;129(1):78– 9. 
16. van der Pal, F., M. van Balken, and J. Heesakkers. "Maintenance percutaneous 
tibial nerve stimulation (PTNS) treatment in successf ully treated patients with 
refractory overactive bladder syndrome: a necessity." Eur Urol 47.Suppl 4  (2005): 
144. 
17. Vandoninck, Vera, et al. "Posterior tibial nerve stimulation in the treatment  of 
urge incontinence." Neurourology and urodynamics 22.1 (2003):  17-23. 
18. Tai C, Shen B, Chen M, Wang J, Roppolo JR, de Groat WC. Prolonged 
poststimulation inhibition of bladder activity induced by tibial nerve stimulation in 
cats. Am J Physiol Ren Physiol. 2011;300(2):F385– 92. 
doi:10.1152/ajprenal.00526.2010. CrossRef  
19. Herbison GP, Arnold EP. Sacral neuromodulation with implanted devices for 
urinary storage and voiding dysfunction in adults. Cochrane Database Syst  Rev. 
2009; Suppl 2:CD004202. doi :10.1002/14651858.CD004202.pub2  
20. Oerlemans, Dennis JAJ, and Philip EV Van Kerrebroeck. "Sacral nerve stimulation for neuromodulation of the lower urinary tract." Continence. Springer 
London, 2009.  217-226. 
 
Human Studies  
2-2-1 Prior Publications of Tibial Nerve Stimulation for Overactive 
Bladder  
McGuire et al. ( 21) first described inhibition of detrusor activity by peripheral 
neuromodulation of the posterior tibial nerve. More recent authors, such as Govier et al. 
(22), van Balken et al. ( 23) and Vandoninc k et al. ( 24), have confirmed a 60– 80% 
positive response rate after 12 weekly treatments with percutaneous tibial nerve 
stimulation. A meta -analysis by Gaziev et al. ( 25) showed level 1 evidence is available 
and supportive of the safety and effectiveness of tibial nerve stimulation for overactive bladder. Data available on the safety of percutaneous tibial nerve stimulation show no 
major concerns for safety. For example, in the 24 month follow -up study to the SUmiT 
trial, the authors found no reported treatment related adverse events in the 50 subjects 
through 24 months ( 26). Four subjects reported five adverse events with unknown 
causes (UTI, pulling feeling on feet , bladder pressure, pinched nerve and slow stream).  
21. McGuire, E. J., et al. "Treatment of motor and sensory detrusor instability by 
electrical stimulation." The Journal of urology 129.1 (1983):  78-79. 
22. Govier, Fred E., et al. "Percutaneous afferent neuromodulation for the refractory 
overactive bladder: results of a multicenter study." The Journal of urology 165.4 
(2001):  1193- 1198.  
23. van Balken, Michael R., et al. "Posterior tibial nerve stimulation as neuromodulative treatment of lower urinary tract dysfunction." The Journal of 
urology 166.3 (2001): 914- 918. 
24. Vandoninck, Vera, et al. "Posterior tibial nerve stimulation in the treatment  of 
urge incontinence." Neurourology and urodynamics 22.1 (2003):  17-23. 
25. Gaziev, Gabriele, et al. "Percutaneous tibial nerve stim ulation (PTNS) efficacy  in 
the treatment of lower urinary tract dysfunctions: a systematic review." BMC 
urology 13.1 (2013): 1.  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 9 of 97   
  
26. Peters, Kenneth M., et al. "Randomized trial of percutaneous tibial nerve 
stimulation versus Sham efficacy in the treatment of overactive bladder 
syndrome: results from the SUmiT trial." The Journal of urology 183.4  (2010): 
1438- 1443.  
27. Finazzi -Agrò, Enrico,  et al. "Percutaneous tibial nerve stimulation effects on 
detrusor overactivity incontinence are not due to a placebo effect: a randomized, 
double- blind, placebo controlled trial." The Journal of urology 184.5 (2010):  2001-  
2006.  
28. Amarenco, G., et al. "Urodynamic effect of acute transcutaneous posterior  tibial 
nerve stimulation in overactive bladder." The Journal of urology 169.6 (2003): 
2210- 2215.  
29. Peters, Kenneth M., et al. "Sustained therapeutic effects of percutaneous  tibial 
nerve stimulation: 24 ‐month results of the STEP study." Neurourology and 
urodynamics 32.1 (2013):  24-29. 
2-2-2 Prior Studies of the Valencia Technologies eCoinTM System  
The eCoinTM system is being tested in an ongoing prospective, multicenter study on 46 
subjects in the United States and New Zealand. A review of the available data on both 
safety and effectiveness of eCoinTM when implanted next to the tibial nerve for treatment 
of urgency urinary incontinence (UUI) is set forth in subsections 2 -2-2-1 and 2-2-2-2. 
The Valencia Technologies eCoinTM system was tested in a prospective, multicenter 
study to confirm the effectiveness and safety of median nerve stimulation using bilateral 
eCoinTM devices in resistant or drug- intolerant hypertensive human subjects . A review of 
the data on safety of eCoin when implanted in the periphery subcutaneously is given in 
subsection 2 -2-2-3. 
2-2-2-1 Effectiveness of eCoinTM Tibial Nerve Stimulation for  UUI 
The feasibility study of eCoinTM tibial nerve stimulation enrolled and implanted 46 
subjects. Two subjects (08- 07 and 07- 06) did not complete an adequate baseline diary 
or follow -up diaries. Age may have been a factor in the inadequate diary completion: 
both subjects were 78 years old. A third subject (07- 17) was explanted prior to receiving 
treatment (device activation). The following analysis excludes data from those three 
subjects.  
 
As of the time of this writing, all 43 subjects have reached three months of follow -up— 
the primary endpoint and the time point for all data presented herein. With an average 
baseline of 5.25 ± 2.93 urge leaks per day, the average change at 3 months is - 3.30 ± 
2.99 (N=43) urge leaks per day. The average percentage change in urge leaks in 
comparison to baseline is - 61%.  
 
Ten of the 43 subjects (23%) show ed no urge leaks (i.e., a 100% improvement); 19 
(44%) showed at least a 75% improvement in urge leaks, and 30 (70%) showed at least 
a 50% improvement.  
 
Patient reported outcomes also showed improvement. Specifically, 72% of subjects (31 
of 43) report improvement of at least 10 points in their quality of life as measured by the 
Incontinence Quality of Life Questionnaire (iQoL). Similarly, the average score on the 
Patient Global Impression of Improvement (PGI -I) scale, which was measured on a 
scale of 1 to 7 from very much worse to very much better, was 5.44.  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 10 of 97   
  
 
In conclusion, the objective diary data and patient reported data show promise for 
eCoinTM as a treatment of UUI.  
2-2-2-2 Safety of eCoinTM Tibial Nerve Stimulation for  UUI 
The feasibility st udy of eCoinTM tibial nerve stimulation implanted 46 subjects; the last 
implantation procedure was performed on October 1, 2017. At the time of this writing, all 
subjects have had the device implanted for at least six months, where one month is the critica l period for the incident of expected related adverse events in a leadless 
neurostimulator. All subjects have also reached the primary endpoint of 3 months. Per protocol, subjects attend an incision check visit two weeks after implantation. They then 
attend a visit one month after implantation at which the wound is reviewed again and 
programming is done. The safety data presented herein reflect all reported and known safety data to date.  
 
Thirteen (13) related adverse events (AEs) and three serious adverse events (SAEs) (one related [SAE#1] and two unrelated [SAE #2 and [SAE#3]) have occurred. For 
purposes of this section, “related” includes “possibly related” as well as “related”. See 
table of related adverse events in Attachm ent 04 -32
. All the AEs have now been 
resolved. Subject 01 -10’s adverse event of mild swelling and Subject 03- 05’s incidence 
of mild to moderate swelling and ankle pain that were previously reported as ongoing are 
now resolved.  
 
The related serious adverse event (SAE #1; Subject 07 -17) involved severe cellulitis of 
the subject’s calf secondary to the ankle wrap. See Attachment 04 -32 for the SAE report 
including the hospital report. The subject was admitted to the hospital with infection and 
given IV antibiotics. The infection was resolved with antibiotics.  Nonetheless, the 
subject desired to have the device explanted, which was done November 1,  2017.  
 
The second serious adverse event (SAE #2) was a limp on the leg where the device was 
implanted. The subject, a patient who did not respond to the therapy and who had 
peripheral edema at screening, desired to have the device removed. The device was 
successfully removed on December 7, 2017. The patient returned for an incision healing 
check on December 21, 2017. The SAE is now resolved with no sequelae. Both the 
center and the DSMB later categorized the SAE #2 as unrelated. Subject also had 
bursitis of the hip, which was inflamed, responded to injections, and later returned once 
effect of injections had worn off.  
 
The third SAE (SAE#3 of 3) was an unrelated incident of pneumonia that resolved.  
 
Finally, there were two slightly misplaced devices (up to one centimeter) at one New Zealand center noticed by the DSMB during review of photographs taken at the subjects’ 
healing check visits. An investigation was opened to determine how the misplacements 
occurred and to decide whether the center should continue implantations. The DSMB 
determined that the center had not used a measurement tool optimally. In response, the 
surgical trainer retrained the appropriate PI on this tool, updated and clarified the 
surgical manual, and communicated with all PIs on the correct use of the measurement 
tool. The DSMB was satisfied that actions taken woul d prevent further misplacements 
and allowed continued implantations at the affected center. The Sponsor believes  that 
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 11 of 97   
  
proctoring of all first implants, as done in the United States where no misplacements 
occurred, provides assurance that all  devices will be optimally placed.  
 
In summary, the safety data suggest that the primary concern is mild to moderate wound 
healing, which resolved in all cases.  
2-2-2-3 Safety of eCoinTM Median Nerve Stimulation for  Hypertension  
The global multicenter feasibility study on hypertension is complete and thus the safety 
data are available for review and presented herein. Among the 48 subjects with 96 
implanted eCoinTM devices, two related Serious Adverse Events (SAEs) (called out as 
“SAE #1” and “SAE #2” in this Section) occurred.  
Nine subjects have experienced inflammation tenderness or redness at the incision site 
or hand. Four subjects have been treated for an infection at the implant site. One of these 
infections occurred six months post implant and led to the explant of the device (SAE #1). 
Three of the four infections occurred at one clinical center which was subsequently shut 
down at the recommendation of the DSMB. One additional explant of a device occurred 
at this same center due to an unconfirmed infection (SAE  #2). All remaining Adverse 
Events were judged to be unrelated to the device or  therapy.  
Attachment 4-12 presents the case report forms for the four reported infections. In 
addition, a fifth case report form is included for w hat the DSMB regarded as an infection 
leading to explant that was not appropriately handled by the center in Ottawa, Canada (Site 12).  
The five subjects who had adverse events of infection or were explanted can be 
summarized as follows: 12- 005 reported moderate bilateral device infection resolved with 
antibiotics; 04- 008 reported severe left arm infection treated initially with antibiotics, but 
ultimately resulting in explantation of device from the left arm; 14 -006 self -reported a mild 
small infection for a few days that resolved on its own; 12 -007 reported mild right forearm 
infection that resolved with antibiotics; and 12- 004 reported middle finger cellulitis initially 
treated with antibiotics, but ultimately resulting in explantation of the device from t he right 
arm. The corresponding adverse event logs, organized according  to patient number, are  
enclosed.  
The DSMB investigation into the higher than average infection rate at Site 12 found that 
the Site was not timely in its filing of adverse event report s; and pointed out that the AE 
on 12- 004 stated that the patient’s swollen middle finger was observed on the day of 
implantation. After discussions with site 12 the DSMB was unconvinced that Site 12 had 
put in place an effective plan for confronting its hi gh infection rate. The DSMB 
recommended suspension of implantation at Site 12 (see attached letter from DSMB – 
Attachment 4-13). After discussions with the Principal Investigator at Site 12, the Company 
decided to suspend indefinitely any further implantations at Site 12.  
2-2-2-4 Conclusions  
Adverse events related to the eCoinTM therapy are associated primarily with inflammation 
or infection at the implant site. In the completed hypertension feasibility study on 48 
subjects with bilateral implants, two subjects had related SAEs (one infection and one 
unconfirmed infection), both of which were resolved by explant of the device.  
In the ongoing OAB feasibility study on 46 subjects, all subjects have been followed at 
least six months post-operatively and the safety results appear slightly better than the  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 12 of 97   
  
aforementioned hypertension study. One subject had a related SAE (severe cellulitis of 
the calf secondary to ankle wrap provided for post -operative care), and two subjec ts had 
unrelated SAEs (one pneumonia and one limp associated with underlying bursitis of the hip and peripheral edema present at screening). The other adverse events were 
associated primarily with wound healing, all of which were resolved.  
 
Executive Summary of Non -Clinical Studies  
Preclinical testing of the eCoinTM subcutaneous neuromodulation system has been 
performed to assure conformance to the design specifications.  
The eCoinTM subcutaneous neuromodulation system was developed under an ISO 
14971:2012 compliant risk management process to identify potential harms and to 
eliminate risk or reduce risks to an acceptable level.  
2-3-1 Bench Testing - eCoinTM Device  
The eCoinTM device is designed to be compliant with all applicable clauses of ISO 
14708- 1:2014 Im plants for surgery –  Active implantable medical devices –  Part 1: 
General requirements for safety, marking and for information to be provided by the 
manufacturer and ISO 14708- 3:2008 Active implantable medical devices -- Part 3: 
Implantable neurostimulator s. 
2-3-1-1  Stimulus Output (207 -1093 2.2.1- 2.2.5, 2.3.1; 207- 1082 2.1 -2.5, 2.8) 
The stimulation output pulse amplitude, current regulation (at loads of 300, 600, 1000, 
1500, and 2500 Ohms), pulse width and pulse rate of the eCoinTM device were verified at 
room temperature, 20 °C, and 45 °C and over battery voltages of 2.7 V, 3 V and 3 .2 V. 
Folder: “VOL_018_IDE Attachment 4 -16 Design Verification and  
Validation Reports ” 
File: “004_207- 1093 SNS Design Verification Test Report.” Refer to 
Sections 2.2.1 -2.2.5 and 2.3.1.  
File: “003_207- 1082 SNS PCBA Verification Test Report.” Refer to 
Sections 2.1- 2.5 and 2.8.  
2-3-1-2 Internal Moisture (207- 1093 2.3.2, 2.3.3)  
Residual gas analysis was performed to verify the internal moisture of the hermetically sealed eCoin
TM device is no more than 1.5%. This test was repeated on eCoinTM devices 
after 24 hour water immersion at 80 °C water and a pressure of 2 atm.  
Folder: “VOL_018 IDE Attachmen t 4-16 Design Verification and  
Validation Reports ” 
File: “004_207- 1093 SNS Design Verification Test Report.” Refer to 
Sections 2.3.2 and 2.3.3.  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 13 of 97   
  
2-3-1-3 Temperature Exposure (207- 1093 2.3.4, 202- 1254)  
The eCoinTM devic e in a sterile pack passed final functional test after one hour of 
temperature exposure at - 10 °C and 55 °C per ISO 14708 -3 clause 26.2. In addition as 
part of the packaging validation, eCoinTM devices passed functional test after exposure 
to climatic cond itioning per ASTM D4332- 13. 
Folder: “VOL_018 IDE Attachmen t 4-16 Design Verification and  
Validation Reports ” 
File: “004_207- 1093 SNS Design Verification Test Repor t.” Refer to 
Section 2.3.4.  
 
Folder: “VOL_020_IDE Attachment 4 -18 Sterile Packaging Validation  
Report ” 
File: “001_4.18 202- 1254 SNS Device Packaging Validation Report”  
2-3-1-4 Pressure Exposure (207- 1093 2.3.5)  
The eCoinTM device passed final functional test after one hour of pressure exposure at 
70 kPa and 150 kPa per ISO 14708- 1:2014 clause 25.  
Folder: “VOL_018 IDE Attachmen t 4-16 Design Verification and  
Validation Reports ” 
File: “004_207- 1093 SNS Design Verification Test Report.” Refer to 
Section 2.3.5.  
2-3-1-5 Random Vibration (207 -1093 2.3.7)  
The eCoinTM device passed final functional test after random vibration at 5 Hz to 500 Hz 
for 30 minutes in each of three mutually perpendicular axes per ISO 14708- 1:2014 
clause 23.2.  
Folder: “VOL_018 IDE Attachmen t 4-16 Design Verification and  
Validation Reports ” 
File: “004_207- 1093 SNS Design Verification Test Report.” Refer to 
section 2.3.7.  
2-3-1-6 Mechanical Shock (207- 1093  2.3.8)  
The eCoinTM device passed final functional test after mechanical shock per ISO 14708-  
1:2014 clause 23.7 (1 ms duration 500 g half -sine).  
Folder: “VOL_018 IDE Attachmen t 4-16 Design Verification and  
Validation Reports ” 
File: “004_207- 1093 SNS Design Verification Test Report.” Refer to 
Section 2.3.8.  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 14 of 97   
  
2-3-1-7 Mechanical Squeeze Test (207- 1093  2.3.9)  
The eCoinTM device passed final functional test following a ten minute exposure to a 
force of 45 N applied to the top center of the device over an area of 0.5 cm squared.  
Folder: “VOL_018 IDE Attachmen t 4-16 Design Verification and  
Validation Reports ” 
File: “004_207- 1093 SNS Design Verification Test Report.” Refer to 
Section 2.3.9.  
2-3-1-8 Battery UL Testing  (EA1821)  
The eCoinTM device battery passed testing per UL 1642 5th edition including short circuit 
(room temperature and 55 °C), abnormal charging, crush, impact , shock, vibration, 
heating, temperature cycling, low pressure and projectile.  
Folder: “VOL_018_IDE Attachment 4 -16 Design Verification and  
Validation Reports ” 
File: “013_EA1821_RPT_Valencia CR1612_UL1642.”  
2-3-1-9 Battery External Short Test (207- 1093  2.3.12)  
The eCoinTM device battery under an external short circuit fault condition was verified to 
generate less than a 2 °C temperature rise at the device surface when implanted 
subcutaneously (ISO 14708- 3:2008 clause 17.1).  
Folder: “VOL_018 IDE Attachmen t 4-16 Design Verification and  
Validation Reports ” 
File: “004_207- 1093 SNS Design  Verification Test Report.” Refer to 
Section 2.3.12.  
2-3-1-10 Electrocautery Immunity Test (207- 1093 2.3.13)  
The eCoinTM device passed final functional test following a 10 second exposure to a 
conducted 500 kHz sine wave delivering 10 V peak to peak between the anode and 
cathode approximating the signal from monopolar electrocautery applied no closer than 
25 cm from the eCoi nTM device.  
Folder: “VOL_018 IDE Attachmen t 4-16 Design Verification and  
Validation Reports ” 
File: “004_207- 1093 SNS Design Verification Test Report.” Refer to 
Section 2.3.13.  
 
2-3-1-11 Corrosion Test (207 -1093 2.4.1)  
No corrosion of the eCoinTM case, feed through anode or cathode in phosphate buffered 
physiological saline at 37 °C was observed after continuous stimulation at maximum 
amplitude until battery depletion.  
Folder: “VOL_018 IDE Attachmen t 4-16 Design Verification and  
Validation Reports ” 
File: “004_207- 1093 SNS Design Verification Test Report.” Refer to 
Section 2 .4.1. 
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 15 of 97   
  
2-3-1-12 Battery Service Life and Elective Replacement (207- 1082 2.6,  2.7; 
201-1016, 201 -1111)  
The eCoinTM battery discharge current and accelerated battery discharge capacity at 37  
°C were used to verify a 2 year service life at nominal amplitude after a 12 month shelf 
life and a 1 year elective replacement at the maximum amplitude after a 12 month shelf 
life. 
Folder: “VOL_018_IDE Attachment 4 -16 Design Verification and  
Validation Reports ” 
File 1: “003_207- 1082 SNS PCBA Verification Test Report.” Refer to 
Sections 2.6 and 2.7.  
File 2: “022_ER 201- 1016 Rev 1 -  CR1612 Battery”  
File 3: “023_ER 201- 1111 Rev 1 –  CR1612 Battery Discharge 
Capacity RIR 419- 356”  
2-3-1-13 Accelerated Life Test (207- 1082 2.9) 
The eCoinTM electronics assembly (PCBA) passed final functional test following a highly 
accelerated life test (HALT) at 125 °C for 1000 hours while under power with a supply 
voltage of 3.2 volts.  
Folder: “VOL_018_IDE Attachment 4 -16 Design Verification and  
Validation Reports ” 
File: “003_207- 1082 SNS PCBA Verification Test Report.” Refer to 
Section 2.9.  
2-3-1-14 Temp erature Cycling Test (207- 1082  2.10)  
The eCoinTM electronics assembly (PCBA) passed final functional test following 
temperature cycling test per MIL -STD-883H Method 1010, Condition B (10 cycles, - 55 
+0/-10 degrees Centigrade to 125 +15/ -0 degrees Centigrade, 10 minute dwell time 
minimum).  
Folder: “VOL_018_IDE Attachmen t 4-16 Design Verification and  
Validation Reports ” 
File: “003_207- 1082 SNS PCBA Verification Test R eport.” Refer to 
Section 2.10.  
2-3-1-15 Laser Seam Weld Validation  (202- 1436)  
The eCoinTM device laser seam weld process was validated (IQ, OQ, PQ) to 
demonstrate that it produces a reliable hermetic seam weld. Acceptance criteria included 
visual inspection, fine leak, gross leak and cross section for weld penetration.  
Folder: “VOL_018_IDE Attachment 4 -16 Design Verification and  
Validation Reports ” 
File: “0 01_202- 1436 PVR SNS Device Seam Weld Top Cover and 
Feed thru Case.”  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 16 of 97   
  
2-3-2 Bench Testing External Controller  
The External Controller is designed to be compliant with all applicable clauses of AAMI / 
ANSI ES60601 -1:2005/(R) 2012 and A1:2012, c1:2009/(R) 2012 and a2:2010/(r) 2012  
(consolidated text) Medical Electrical Equipment – Part 1: General requirements for 
basic safety and essential performance, IEC 60601- 1-2:2014 Medical electrical 
equipment – Part 1 -2: General requirements for basic saf ety and essential performance  
– Collateral standard: Electromagnetic disturbances -  Requirements and tests.  
2-3-2-1 External Controller Output (207 -1541 4.2.1-  4.2.8)  
The External Controller was verified to meet all output command and command data 
transmission and  timing requirements.  
Folder: “VOL_018_IDE Attachment 4 -16 Design Verification and  
Validation Reports ” 
File: “005_207- 1541 SNS External Controller Verification Test 
Report.” Refer to Sections 4.2.1 –  4.2.8.  
2-3-2-2 External Controller Battery Discharge and Charge Time (207- 1541 
4.2.9,  4.2.10)  
The External Controller was verified to provide at least 7 days of standby operation and 
15 minutes of transmit operation on a single battery charge. The External Controller 
charging with fully discharged battery was verified to complete within 6 hours.  
Folder: “VOL_018_IDE Attachment 4 -16 Design Verification and  
Validation Reports ” 
File: “005_207- 1541 SNS External Controller Verification Test 
Report.” Refer to Sections 4.2.9 and 4.2.10.  
2-3-2-3 External Controller Battery Safety Testing (RSZBHST 160325326, 
VTC-002A (IEC 60950 -1 4.3.8), 2 07-1541 4.2.11 – 4.2.13,  4.2.15)  
The External Controller rechargeable Li -polymer battery has undergone safety testing 
and passed per IEC62133:2012. In addition, the battery protection circuitry for over - 
charging, over -discharge, and over -heating were veri fied to operate as specified. Battery 
short -circuit protection was verified to operate as specified and also passed testing per 
IEC 60950- 1 4.3.8.  
Folder: “VOL_018_IDE Attachmen t 4-16 Design Ver ification and  
Validation Reports ” 
File 1: “014_005_RSZBHST 160325326.”  
File 2: “021_External Controller Safety Testing VTC_002A IEC 
60601- 1 3rd ed Ec01 Remote.”  
File 3: “005_207- 1541 SNS External Controller Verification Test 
Report.” Refer to Sections 4.2.11 – 4.2.13 and 4.2.15.  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 17 of 97   
  
2-3-2-4 External Controller Over -heat Shutdown (207 -1541 4.3.2,  4.3.3)  
The External Controller has been verified to shut -down transmission if the temperature 
of the device exceeds 48 °C.  
Folder: “VOL_018_IDE Attachmen t 4-16 Design Verification and  
Validation Reports ” 
File: “005_207- 1541 SNS External Controller Verification Test 
Report.” Refer to Sections 4.3.2 and 4.3.3.  
2-3-2-5 External Controller IEC 60601- 1 (VTC -002A)  
The External Controller has passed applicable clauses of IEC 60601- 1: 2005 + CORR. 1 
(2006) + CORR. 2 (2007) + AM1 (2012) or IEC 60601- 1: 2012. This includes clauses 5 .7 
Humidity, 8.7 Leakage Current, 8.8.3 Dielectric Strength, 8.8.4.1 Enclosure Ball 
Pressure Test, 11.1.1 Excessive Temperatures, 11.6.1 Cleaning, Sterilization 
Disinfection and 15.3 Mechanical Strength (Push, Drop and Mould Stress Relief).  
Folder: “VOL_01 8_IDE Attachment 4 -16 Design Verification and  
Validation Reports ” 
File: “021_External Controller Safety Testing VTC_002A IEC 60601- 1 
3rd ed Ec01 Remote”  
File Attac hments: “017_External Controller Safety Testing VTC - 
002A Attachment A Photographs;” “018_External Controller Safety 
Testing VTC -002A Attachment B Schematics;” “019_External 
Controller Safety Testing VTC -002A Attachment C Calibration;” and 
“020_External Co ntroller Safety Testing VTC -002A Attachment D 
Specifications.”  
2-3-3 MR Compatibility  
The eCoinTM Subcutaneous Neuromodulation System has been evaluated for safety and 
compatibility in the MRI environment and is considered MRI Conditional . Patients with 
the eCoi nTM implant can safely  undergo Magnetic Resonance Imaging (MRI)  for head, 
neck, or shoulder so long as the device remains outside of the machine and in magnetic 
fields of less than or equal to 152 ± 10 Gauss/cm . Additional details can be found in the 
eCoin MR Labeling.  
2-3-4 Electrical Safety and Electromagnetic Compatibility  
2-3-4-1 Electromagnetic Non -Ionizing Radiation Immunity (SD72116479-  
0516, 207- 1093 2.3.6)  
The eCoinTM device passed final functional test after and remained immune during 
exposure to electromagnetic non- Ionizing radiation per ISO 14708 -3 Clause 27.  
Folder: “VOL_018_IDE 4 -16 Design Verification and Validation 
Reports ” 
File 1: “016_SD72116479- 0516- 0516 CISPR 11 Class B ESD and  
ISO14708 -3 Test Report.” Refer to Section 4.  
File 2: “004_207- 1093 SNS Design Verification Test Report.” Refer 
to Section 2.3.6.  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 18 of 97   
  
2-3-4-2 Current Leakage (207- 1093 2.3.10)  
The direct current leakage between the anode and cathode of the eCoinTM was verified 
to be less than less than 0.75 microamperes / square millimeter of electrode surf ace per 
ISO 14708- 3 clause 16.2. Notes: For a direct current leakage less than 1 microampere, 
the 4.0 ±0.2mm diameter cathode current density is less than 0.08 microamperes per 
mm-squared. The cathode is worst case since it has a smaller surface area than the 
anode.  
Folder: “VOL_018 IDE Attachmen t 4-16 Design Verification and  
Validation Reports ” 
File: “004_207- 1093 SNS Design Verification Test Report.” Refer to 
Sect ion 2.3.10.  
2-3-4-3 Insulation Leakage (207- 1093  2.3.11)  
After preconditioning by total immersion into 9 g/l saline at 37 °C for at least 10 days, the eCoin
TM insulation at maximum stimulation amplitude was verified to be greater than 3.3 
kOhm based on no more than a 10% reduction in amplitude when the load is reduced 
from 600 Ohms to 300 Ohms (measured greater than 30 kOhm) . 
Folder: “VOL_018 IDE Attachmen t 4-16 Design Verification and  
Validation Reports ” 
File: “004_207- 1093 SNS Design Verification Test Report.” Refer to 
Section 2.3.11.  
2-3-4-4 Electrostatic Discharge (SD72116479- 0516)  
The eCoinTM device passed final functional test and demonstrated safe operation after 
exposure to electrostatic discharge per IEC 61000 -4-2 up to +  8 kV direct contact and up 
to + 15 kV air discharge.  
Folder: “VOL_018 IDE Attachmen t 4-16 Design Verification and  
Validation Reports ” 
File: “016_SD72116479- 0516 CISPR 11 Class B ESD and ISO14708- 3 
Test Report.” Refer to Section 3.1.  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 19 of 97   
  
2-3-5 Electrical Safety and EMC External Controller  
2-3-5-1 Electromagnetic Emissions and Non -Ionizing Radiation Immunity 
(SD72110544- 1015)  
The External Controller has undergone testing and passed EMC emissions and 
immunity per IEC 60601- 1-2:2014. This includes radiated and conducted emissions per 
CISPR 11 Class B, harmonic current emissions per EN61000- 3-2 Class A and voltage 
fluctuations and flicker per EN 61000 -3-3. Immunity testing includes electrostatic 
discharge per IEC 61000 -4-2, amplitude modulated RF EM fields per IE C 61000- 4-3, 
proximity RF fields from wireless communication equipment per IEC 61000- 4-3, 
electrical fast transients per IEC 61000- 4-4, surge per IEC 61000 -4-5, RF common 
mode per IEC 61000 -4-6, power magnetic field of 30 A/m at 50Hz and 60 Hz per IEC 
61000 -4-8 and voltage dip and interruptions per IEC 61000- 4-11. 
Folder: “VOL_018 IDE Attachmen t 4-16 Design Verification and  
Validation Reports ” 
File: “015_SD72110544- 1015 External Controller EMC Test Report.” 
Refer to Section 3.  
2-3-6 Software eCoinTM Device (209 -1035, 209 -1061, 303 -1122)  
The level of safety concern for the eCoinTM device firmware is Moderate since a failure or 
latent design flaw could directly result in a minor injury to the patient by leading to 
uncomfortable levels of stimulation and/or the need for premature device explant.  
Folder: “VOL_018 IDE Attachmen t 4-16 Design Verif ication and  
Validation Reports ” 
File 1: “006_209- 1035 SNS Firmware Verification Test Report”  
File 2: “007_209- 1061 Firmware Unit Test Report” (plus 008_209-  
1061 Appendix A & 009_209- 1061 Appendix B)  
File 3: “024_209- 3264 Rev 1 - SNS Firmware Verification Test Report 
OAB”  
Folder: “VOL_028_IDE Attachment 4 -26 303-1122 Software Design 
Specification SNS ” 
File: “001_4.26 303- 1122 Software Design Specification SNS.”  
2-3-7 Software External Controller (207-1541,  303-1122 ) 
The level of safety concern for the External Controller firmware is Minor since its function is limited such that a failure or design flaw is unlikely to cause any injury to the patient or operator. Verification and validation testing has been completed with all software design 
requirements met.  
Folder: “VOL_018 IDE Attachmen t 4-16 Design Verification and  
Validation Reports ” 
File: “005_207- 1541 SNS External Controller Verification Test 
Report.”  
Folder: “VOL_028_IDE Attachment 4 -26 303-1122 Software Design 
Specification SNS ” 
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 20 of 97   
  
File: “001_4.26 303- 1122 Software Design Specification SNS.”  
2-3-8 Biocompatibility  
2-3-8-1 Cytotoxicity ISO 10993- 5 (PBL  14E0355G -M01G)  
Based on the qualitative evaluation of cells exposed to eCoinTM test a rticle extract, the 
eCoinTM test article was not considered to have a cytotoxic effect (no reactivity).  
Folder: “VOL_029 IDE Attachmen t 4-27 Biocompatibility Reports ” 
File: “001_Cytotoxicity Pacific BioLabs Study No. 14E0355G -M01G.”  
2-3-8-2 Sensitization ISO 10993- 10 (PBL  14H0049G -X01G)  
Under the conditions of the study, the eCoinTM test article did not elicit sensitization 
reactions.  
Folder: “VOL_029_IDE Attachment 4 -27 Biocompatibility Reports ” 
File: “002_Report Sensitization Pacific BioLabs Study 
No 14H0049G -X01G.”  
2-3-8-3 Irritation ISO 10993 -10 (PBL  14H0048G -X01G)  
Based on erythema and edema scores, no irritation was noted with the eCoinTM test 
article when compared to control. Under the conditions of the study, the eCoinTM test 
article met the requirements for the Intracutaneous (Intradermal) Reactivity Test.  
Folde r: “VOL_029_IDE Attachment 4 -27 Biocompatibility Reports ” 
File: “003_Irritation Pacific BioLabs Study No 14H0048G -X01G.”  
2-3-8-4 Acute Systemic Toxicity ISO 10993- 11 (PBL  14H0051G -X01G)  
None of the anim als treated with eCoinTM test article extract exhibited a greater 
biological activity when compared to those treated with the control. Under the conditions 
of the study, the eCoinTM test article met the requirements of ISO 10993- 11. 
Folder: “VOL_029_IDE At tachmen t 4-27 Biocompatibility Reports ” 
File: “004_Acute Systemic Toxicity Pacific BioLabs Study No 
14H0051G -X01G.”  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 21 of 97   
  
2-3-8-5 Sub- Chronic Systemic Toxicity 90 Day ISO 10993- 6 (PBL 16C0069G - 
X01G)  
The results suggest that the device, when implanted subcutaneously, was well -tolerated 
in male and female Sprague Dawley rats over a period of 94 days. There was no 
evidence of test article effect on body weights and body weight changes. Changes in 
several hematology and clinical chemistry parameters that reached statistical 
significance were not considered test article related because they appeared to be 
sporadic and values were within the normal range typical for this animal species. There 
were no statistically significant differences in coagulation factors.  
There were no microscopic observations in the systemic tissues or organs of male and 
female rats that were considered to be related to the subcutaneous implantation of the 
test article. There were two notable lesions that were identified macroscopically in two 
female rats from the test group; a lump present near the implant site (Animal #13) and 
right eye opacity (Animal # 12). The lesion near the implant site observed in one female 
animal was identified as M -adenocarcinoma of mammary gland and was considered 
incidental. The ocular changes observed in Animal #12 were considered to be of a 
traumatic etiology. The local, subcutaneous tissue response to both the control article 
and test artic le was comparable for male and female rats as characterized primarily by 
fibrosis, neovascularization, and cellular infiltrates.  
Folder: “VOL_029 IDE Attachmen t 4-27 Biocompatibility Reports ” 
File: “005_Sub -chronic Toxicity Pacific BioLabs Study No.  
16C0069G -X01G.”  
2-3-8-6 Genotoxicity ISO 10993- 3 (PBL 14E0349G -X01G, 16E0213G -X01G)  
Based on the criteria and conditions the Bacterial Mutagenicity Test (Ames Assay) used, the eCoin
TM test article was considered non- mutagenic. In a ISO 10993 -3:2014 
compliant mouse lymphoma assay, the mutant frequencies and cloning efficiencies of 
preparations treated with the eCoinTM test article were within limits defined for a negative 
response. Accor dingly, the eCoinTM is considered to be non -mutagenic and non-  
clastogenic in the mouse lymphoma assay test  system.  
Folder: “VOL_029 IDE Attachmen t 4-27 Biocompatibility Reports ” 
File 1: “006_Genotoxicity AMES PBL No 14E0349G -X01G.”  
File 2: “007_Genotoxicity Mouse Lymphoma 16E0213G -X01G.”  
2-3-8-7 Implantation 90 Day ISO 10993- 6 (PBL  14E0356G -X01G)  
Under the conditions of the study, the eCoinTM test article was considered a non- irritant 
to the tissue as compared to the negative control article.  
Folder: “VOL_029 IDE Attachmen t 4-27 Biocompatibility Reports ” 
File: “008_Implantation Pacific BioLabs Study No. 14E0356G -X01G.”  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 22 of 97   
  
2-3-8-8 Pyrogen - Material Mediated ISO 10993- 11 (PBL 16C0182G -X01G) 
The test was performed according to ISO 10993- 11 and USP <151> guidelines. All 
animals appeared healthy during the test and none of the tested rabbits exhibited 
individual increase in temperature greater  or equal to 0.5°C when compared to the 
control temperature. Based on criteria for this test, the test article meets USP <151> requirements for the absence of  pyrogens.  
Folder: “VOL_029_IDE Attachment 4 -27 Biocompatibility Reports ” 
File: “009_Material -Mediated Pyrogenicity 16C0182G -X01G.”  
2-3-8-9 Ethylene Oxide Sterilization Residuals ISO 10993- 7 (Nelson 749416) 
The ethylene oxide residual for the eCoi nTM device was less than 0.012 mg (1.2 
micrograms per centimeter squared of device surface area). The ethylene chlorohydrin 
residual for the eCoinTM device was less than 0.038 mg (3.8 micrograms per centimeter 
squared of device surface area). Both of these  are within the ISO 10993 -7 limit for 
permanent implants and the tolerable contact  limit. 
Folder: “VOL_029_IDE Attachmen t 4-27 Biocompatibility Reports ” 
File: “010_EO Residuals 749416 8XL.”  
2-3-9 Particulate (Nelson Lab Number 884283-01)  
The eCoinTM device particulate counts meet requirements per ISO 14708 -1:2014 clause 
14.2.  
Folder: “VOL_018_IDE Attachment 4 -16 Design Verification and 
Validation Reports ” 
File: “010_884283- S01 Particulate Test.”  
2-3-10 Sterility (20 02-1206)  
The eCoinTM device ethylene oxide sterilization process was validated per ISO 11135 
using half cycle batch release approach with t he over kill method (ISO 11135- 1:2007(E) 
Annex B).  
Folder: “VOL_019_IDE Attachment 4 -17 Ethylene Oxide Sterilization 
Validation Reports ” 
File: “001_Ethylene Oxide Sterilization Validation Reports”  
2-3-11 Packaging (202-1254; Westpak 225-15 -0053A)  
Validation of the eCoinTM device packaging demonstrated that the integrity of the final 
package is maintained under the severities of distribution, storage and handling. After 3x 
(worst case) sterilization, baseline samples were tested for seal strength per ASTM 
F88M:2009 and seal integrity per ASTM F1886 -09. Remaining samples underwent 
climatic conditioning followed by shipping and handling testing per ASTM D4169 -14. 
Zero- aged samples were then tested for seal strength per ASTM F88M:2009 and seal 
integrity per ASTM F1886- 09. Remaining samples underwent accelerated and real time 
shelf -life aging (see 2-3-12). 
Folder: “VOL_020_IDE Att achmen t 4-18 Sterile Packaging Validation 
Report ” 
File 1: “001_202- 1254 SNS Device Packaging Validation Report.”  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 23 of 97   
  
File 2: “003_Appendix B Test Lab Report No 225 -15-0053A”  
2-3-12 Shelf Life (202 -1254; Westpak 225 -15-0053B, 225 -15-0053C)  
Accelerated and real time aging of the eCoinTM device and its packaging demonstrated 
that the integrity of the final package and device functionality is maintained over the 1 
year device shelf -life. Accelerated aging equivalent to a 13 month shelf life was 
completed per ASTM F1980- 07. Real -time aging for 13 months was completed at 
ambient conditions (approximately 25 °C and 50% relative humidity). After aging, 
packaging samples were then tested for seal strength per ASTM F88M:2009 and seal 
integrity per ASTM F1886- 09 and the eCoinTM device underwent final functional testing.  
Folder: “VOL_020_IDE Attachmen t 4-18 Sterile Packaging Validation 
Report ” 
File 1: “001_202- 1254 SNS Device Packaging Validation Report” 
File 2: “004_Appendix C Test Lab Report No 225- 15-0053B.”  
File 3: “005_Appendix C Test Lab Report No 225- 15-0053C 13 Month 
Real Time Aging of the SNS.”  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 24 of 97   
  
 
 
 
Purpose  
This investigation is designed as a pivotal study of the safety and effectiveness of the 
Valencia Technologies eCoinTM system in the treatment of urgency urinary incontinence. 
This study is designed to develop sufficient safety and effectiveness data to be 
incorporated in a Pre- Market Approval Application.  
 
Valencia Technologies Corporation, the Sponsor, manufactures the study device, 
eCoinTM (electroceutical coin). eCoinTM is an investigational device to be utilized in the 
treatment of patients with urgenc y urinary incontinence (UUI).  
 
Up to 135 subjects, with a target of 120 subjects will be consented and enrolled to 
participate in the study. Only subjects meeting all inclusion and exclusion criteria will be 
enrolled.  
 
Each person will participate in the s tudy for up to 63 weeks (up to 15 weeks between 
screening and device activation plus 48 weeks of follow -up). 
The primary aims are to evaluate the safety and effectiveness of eCoinTM for the 
treatment of UUI.  
 
Summary  
This prospective, multicenter, single- arm trial will evaluate the safety and effectiveness 
of eCoinTM tibial nerve stimulation in subjects with urgency urinary incontinence (UUI) as 
defined by the American Urological Association ( 30). The study will evaluate changes 
from baseline in OAB symptoms as measured by voiding diaries and patient -reported 
outcomes through 48 weeks of eCoinTM therapy (which is the same as 52 weeks from 
study device implantation). The primary outcome wil l be measured at 48 weeks of 
eCoinTM therapy; the key secondary outcomes will be measured at 24 weeks of eCoinTM 
therapy. Safety will be summarized by data on reportable adverse events and device 
deficiencies.  
 
The eCoinTM neuromodulation device will be im planted subcutaneously in the right or left 
leg of subjects with UUI. After a 4 week implant healing period, all subjects will have a 
programming visit where the device is activated (turned ON). After 48 weeks (occurring 
about 52 weeks post -implant), the primary effectiveness and primary safety endpoints 
will be assessed.  
30. American Urological Association, OVERACTIVE BLADDER DIAGNOSIS  AND 
TREATMENT OF OVERACTIVE BLADDER IN ADULTS AUASUFU  Guideline 
(2012); Amended  (2014).  
3 Investigational  Plan  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 25 of 97   
  
Protocol  
3-3-1 Study Design  
This trial is a prospective, multicenter, single- arm study of the safety and effectiveness of 
eCoinTM tibial nerve stimulation in subjects having UUI.  
 
Subjects will be screened. Up to 135 subjects, with a target of 120 subjects, who meet 
all inclusion and exclusion criteria will be enrolled to participate. All subjects will be 
scheduled to receive the investigational therapy (eCoinTM for UUI).  
 
This document may refer to eCoinTM as “eCoinTM,” “eCoinTM therapy”, the “eCoinTM 
system,” or the “study device.” All such terms refers to the active study device called 
eCoinTM by the manufacturer.  
3-3-2 Subject  Selection  
3-3-2-1 Patient  Population  
The primary sample size target is 120 subjects having UUI. For enrollment, eligible 
subjects will be consented and entered into a baseline evaluation period to confirm study 
eligibility. Baseline assessment will include complete medical history, physical 
examination, and completion of a 3 -day voiding diary to quantify voiding behavior, 
symptoms, and incontinence. Only subjects who meet all the inclusion and exclusion 
criteria, and have provided informed consent, will be enrolled.  
 
All eligible enrolled subjects will be scheduled to be implanted with the eCoinTM system 
after baseline assessment. The investi gator will select the side of implantation.  
Approximately 4 weeks post implantation, subjects will return for a programming visit at 
which time the device will be activated. A programming technician will implement the 
activation procedure, setting amplitude of stimulation according to the upper level of a 
subject’s comfort.  
 
 
3-3-2-2 Selection  Criteria  
Participants shall be screened in accordance with the following inclusion and exclusion 
criteria.  
 
Inclusion Criteria  
1. Women and men between 18 and 80 years  old. 
2. Diagnosis of overactive bladder with urgency urinary incontinence or  mixed 
urge and stress incontinence with a predominant urgency component (self - 
reported), for at least 6 months.  
3. Individual has at least one urgency urinary incontinence episode on each of 
three days as determined on a 3- day voiding diary.  
4. Individual gives written informed  consent.  
5. Individual is mentally competent and able to understand all study  requirements.  
6. Individual is willing and able to complete a 3 -day voiding diary and quality of life 
questionnaire.  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 26 of 97   
  
7. Individual is without pharmacological treatment of overactive bladder 
(antimuscarinics and β3 -adrenoceptor agonists) for 2 weeks prior to baseline or 
longer if the investigator judges that the therapeutic effec t is still present.  
8. Individual is intolerant of or has an inadequate response to any of 
anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, or percutaneous 
tibial nerve  stimulation.  
. 
 
Exclusion Criteria  
1. Individual has predominantly stress urinary incontinence with more than 1/3 
stress urinary incontinent episodes when compared to total urinary  incontinent 
episodes.  
2. Individual has clinically significant bladder outlet obstruction. (Suspected bladder 
outlet obstruction wi ll be initially assessed by uroflow study with those having a 
maximum flow rate < 15mL/s requiring additional  evaluation.)  
3. Individual has clinically significant pelvic organ prolapse beyond the hymenal 
ring. 
4. Individual has had a prior anti -stress incontinence operation within the last  year.  
5. Individual has known polyuria.  
6. Individual has significant lower urinary tract pain or has been diagnosed  with 
interstitial cystitis or bladder pain syndrome.  
7. Individual has abnormal post void residual (i.e., greater than 200 cc initially and 
on repeat testing after double voiding).  
8. Individual has clinically significant urethral stricture disease or bladder neck contracture. (Suspected disease or contracture will be initially assessed by 
uroflow study with those having a m aximum flow rate < 15mL/s requiring 
additional  evaluation.)  
9. Individual has an active urinary tract infection at time of  enrollment.  
10. Individual has recurrent urinary tract infections defined as 4 or more UTI’s in the 
last 12  months.  
11. Individual has peripheral arterial  disease.  
12. Individual has chronic venous insufficiency with a history of skin change (hyperpigmentation, lipodermatosclerosis, ulceration) in the ankle region.  
13. Individual has morbid obesity and in the opinion of the investigator is not a good candidate for the study.  
14. Individual has had diagnosis of bladder, urethral, or prostate cancer.  
15. Individual has neurogenic bladder  dysfunction.  
16. Individual is taking an alpha- blocker for benign prostatic  hyperplasia.  
17. Individual is pregnant or intends to become pregnant during the  study.  
18. Individual is breast feeding or is less than 9- months  post-partum.  
19. Individual is participating or intends to participate in another interventional clinical study during this  study.  
20. Individual has the  presence of urinary fistula, bladder stone, or interstitial  cystitis.  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 27 of 97   
  
21. Individual has uncontrolled diabetes mellitus (Hemoglobin A1C>7) or diabetes 
with significant peripheral complications. (Uncontrolled diabetes will be ruled out 
by blood test excluding those with Hemoglobin A1C>7).  
22. Individual has an implantable neurostimulator, pacemaker, or implantable cardiac defibrillator  (ICD).  
23. Individual has been previously treated with sacral nerve stimulation.  
24. Individual has been treated with onabotulinumtoxinA in the previous 9 months 
prior to enrollment.  
25. Individual has been treated with percutaneous tibial nerve stimulation (PTNS) 
within the previous 4 weeks prior to enrollment or more time if the principal 
investigator judges that the therapeutic effect is  present.  
26. Individual is currently using transcutaneous electrical nerve stimulation (TENS) 
in the pelvic region, back, or  legs.  
27. Individual is aware that he or she will need an MRI scan during the study  period.  
28. Individual has a clotting or bleeding disorder and in the opinion of the 
investigator is not a good candidate for the study (antiplatelet and  anticoagulant 
therapy may be continued or held at the discretion of the  investigator).  
29. Individual has a clinically significant peri pheral  neuropathy.  
30. Individual has nerve damage that could impact either the tibial nerve or  pelvic 
floor function.  
31. Individual is neutropenic or  immune -compromised.  
32. Individual has had previous surgery and/or significant scarring at the implant 
location.  
33. Individual has pitting edema at implant location ( ≥ 2+ is  excluded).  
34. Individual has ongoing dermatologic condition at the implant site, including but 
not limited to dermatitis and autoimmune disorders.  
35. Individual has inadequate skin integrity or any evidence of an infection or 
inflammation in either lower  leg. 
36. Individual has a history of infection in the involved lower  leg. 
37. Individual has varicose veins and is symptomatic.  
38. Individual has varicose veins in the involved lower leg or both lower  legs.  
39. Individual has bladder stones or neoplasia. (Suspected bladder stones or neoplasia will be ruled out with a urine dipstick showing no more than  trace 
blood.)  
40. In the opinion of the investigator, Individual is not a good candidate for 
participation in the  study.  
3-3-3 Ethical  Considerations  
This study involves no critical ethical issue. Subjects who are refractory to second or 
third line therapy have the potential to gain a new treatment modality through participation in the study and to assess the impact of this treatment modality on their 
incontinence with minimal risk.  
• All subjects will receive tibial nerve stimulation with the eCoin
TM device for 48 
weeks offering them an opportunity to try an investigational therapy that might 
provide benefit.  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 28 of 97   
  
• While other device modalities are more invasive (i.e., sacral neuromodulation or 
botulinum toxin of the bladder) and drug therapy is fraught with poor  compliance, 
as an investigational device, the study will only include patients who have an 
inadequate response to second or third line therapies.  
• Some subjects may not receive clinical benefit from eCoinTM therapy, but are to 
continue with follow -up until study completion even if they ask for eCoinTM to be 
explanted. Some individuals who initially do not r eceive clinical benefit may 
benefit from late response and cumulative effects of  treatment.  
• Subjects are intended to be without pharmacological medications for  overactive 
bladder. If the addition of medications is medically necessary as described 
herein, s uch information will be collected and reported.  
 
Study Procedures  
All subjects  will be followed  for 48 weeks  post-activation (which  is the same as 52 weeks 
post-implantation). A 3- day voiding diary will be collected that reports the number and 
type of incontinence episodes,  number  of micturitions;  and administering questionnaires 
including the OABq,  and PGI-I at 4, 8, 12, 24, 36, and 48 weeks  post-activation.  
The follow -up study visits are described in relationship to the initial activation visit 
occurr ing 4 weeks after implantation of the study device. Thus, 52 weeks post - 
implantation occurs at the 48 weeks post -activation visit, and 28 weeks post - 
implantation occurs at the 24 weeks post -activation visit. See Visit Overview 3- 4-2 for 
exact timing of s uch visits. For any enrolled subject who is not activated, the same 
schedule will be followed as if the subject were activated.  
All subjects are expected to remain free of pharmacological medications for overactive 
bladder, unless medically necessary, unti l the primary endpoint is measured at 48 weeks 
post-activation. Subjects who are taking pharmacologic medication at screening should 
be washed off OAB medications for a period of 2 weeks prior to the baseline visit.  
All subjects  will either  be explanted after the study  visit at 48 weeks  post-activation,  or, if 
they consent to extended follow up, they will be explanted shortly after their 96 week 
post-activation visit or their 144 week post -activation visit. 
COVID -19 Considerations  
Due to the COV ID-19 pandemic, subjects may not be able or would be at risk coming 
in to the investigational site for remaining follow up visits. As an alternative, subjects 
may complete remote visits, in which all study activities can be performed  with the 
exception of taking vitals. The patient will electronically transmit their diary and OABq 
responses to the investigational site personnel, through either pictures, scans, or fax, 
and review all other items over the phone. Changes in study visit schedules, remote 
visits , missed visits, or patient discontinuations due to COVID -19 will be documented 
and will be included in the final study visit report.  
3-4-1 Recruitment Plans  
Investigators will identify patients who are currently under their direct care, and contact patients who appear to qualify from medical records. Investigators will also seek 
referrals from other urology, urogynecology, gynecology, and primary care practices. A 
member of the site’s clinical research team shall assess whether the individual seems 
suitable for  the study. The patient should have a medical history of overactive bladder 

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 29 of 97   
 with urgency urinary incontinence. Patients with urgency urinary incontinence who 
appear to meet the inclusion/exclusion criteria from medical records will be contacted by 
the Investigator or designated study staff and presented with the opportunity to 
participate in the study, including:  
• reason for being identified (OAB with urgency urinary  incontinence)  
• description of  therapy  
• potential  benefits  
• potential  risks 
• compensation (see  3-11-6) 
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 30 of 97   
  
Patients who remain interested will be brought into the research clinic for further 
screening and informed consent.  
 
3-4-2 Visit Overview  
The ordered enrollment process consists of screening (including obtaining written 
consent), completing the baseline evaluation, implanting the eCoinTM system, and 
establishing the participant’s amplitude setting. This Section includes a table of the visit 
schedule and contents thereof. The timing of visits 1 through 4, 12 and 13, is described 
in relationship to the visit named, while the timing of visits 6 through 11 is described in 
relationship to the initial activation visit (Visit 5). A revision procedur e would not reset 
the initial activation date.  
 
For visits involving a 3 -day diary, the diary should be completed over 3 consecutive days 
during the 7 days prior to each indicated visit. The site should give patients a telephone 
call to remind them of the diary requirement at least 3 days prior to each follow -up visit.  
• Visit 1: Screening Procedures (informed consent, urinalysis, PVR, history  and 
physical examination, subjects begin 2 week wash- off of OAB medications if 
applicable, concomitant medication therapy review, eligibility  determination)  
• Visit 2: Baseline Assessments (3 -day voiding diary, OABq, subject receive TENS 
instructions, final eligibility determination) (Time: Between 3 and 28 days from 
Visit 1) 
• Visit 3: Implant Procedure (Return of 3 -day voiding diary completed alongside 
TENS, adverse event assessment, concomitant therapy review, patient surveys 
including OABq, patient satisfaction, and patient global impression of 
improvement, return of the TENS  unit, pre and post -op pictures) (Time: Between 
7 and 35 days from Visit  2) 
• Visit 4: Incision Healing Check (week 2) (Time: Between 9 and 19 days from  Visit 
3) including pictures  
• Visit 5: Initial Activation (week 4) (Time: Between 23 and 43 days from Visit  3) 
including pictures  
• Visit 6 (4 weeks post -activation): Follow -up Assessments (3- day voiding diary, 
adverse event assessment, concomitant medication therapy review, patient 
surveys including OABq, patient satisfaction, and patient global impression of 
improvement) (Time: Between 23 and 33 days from Visit  5) 
• Visit 7 (8 weeks post -activation): Follow -up Assessments (3- day voiding diary, 
adverse event assessment, concomitant medication therapy review, patient 
surveys including OABq, patient satisfaction, and  patient global impression of 
improvement) (Time: Between 51 and 61 days from Visit  5) 
• Visit 7b (8 weeks post -activation): Second programming to make any 
adjustments (Time: Between 51 and 68 days from Visit 5; Visit 7b may occur on the same day as Visit 7 or about one week following Visit  7) 
• Visit 8 (12 weeks post -activation): Follow -up Assessments (3 -day voiding diary, 
adverse event assessment, concomitant medication therapy review, patient 
surveys including OABq, patient satisfaction, and patient global i mpression of 
improvement) (Time: Between 79 and 89 days from Visit  5) 
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 31 of 97   
  
• Visit 9 (24 weeks post -activation): Follow -up Assessments (3 -day voiding diary, 
adverse event assessment, concomitant medication therapy review, patient 
surveys including OABq, patient satisfaction, and patient global impression of 
improvement) (Time: Between 163 and 173 days from Visit  5) 
• Visit 9b (24 weeks post -activation, described elsewhere as 28 weeks post - 
implantation): Third programming to make any adjustments (Time: Between 163 
and 180 days from Visit 5; Visit 9b can occur on the same day as Visit 9 or  about 
one week following Visit  9) 
• Visit 10 (36 we eks post -activation): Follow -up Assessments (3- day voiding diary, 
adverse event assessment, concomitant medication therapy review, patient 
surveys including OABq, patient satisfaction, and patient global impression of 
improvement) (Time: Between 247 and 257 days from Visit  5) 
• Visit 10b (36 weeks post -activation): Fourth programming to make any 
adjustments (Time: Between 247 and 264 days from Visit 5; Visit 10b can occur 
on the same day as Visit 10 or about one week following Visit  10) 
• Visit 11 (48 weeks pos t-activation, described elsewhere as 52 weeks post - 
implantation): Follow -up Assessments (3 -day voiding diary, adverse event 
assessment, concomitant medication therapy review, patient surveys including 
OABq, patient satisfaction including final study quest ionnaire, and patient global 
impression of improvement) May be done remotely if necessary with 
consideration to COVID -19. (Time: Between 331 and 341 days from Visit  5) 
• Visit 12 (For subjects who consent to extended follow up and have their device in 
place at 2 years) (96 weeks post -activation): Follow -up Assessments (3- day 
voiding diary, adverse event assessment, concomitant medication therapy 
review, patient surveys including OABq, patient satisfaction, and patient global 
impression of improvement) (Time: Between 662 and 682 days from Visit  5) 
• Visit 13 (For subjects who consent to extended follow up and have their device in 
place at 3 years) (144 weeks post -activation, described elsewhere as 52 weeks 
post-implantation): Follow -up Assessments (3- day voiding diary, adverse event 
assessment, concomitant medication therapy review, patient surveys including 
OABq, patient satisfaction, and patient global impression of improvement) (Time: 
Between 998 and 1,018 days from Visit  5) 
• Visit 14: Explant Visit (Time for those not consenting to follow up through 3 years: 
Between 0 days and 15 days from Visit 11) (Time for those consenting to follow 
up through 3 years: Between 0 days and 15 days from Visit 12 or from Visit 13) 
including pre and post -op pictures  
• Visit 15: In cision Healing check (2 weeks post -explantation): visit to assess 
wound healing including pictures. (Time: Between 9 and 19 days from Visit  14). 
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 32 of 97   
  
 
Screening  
Baseline  
Implantation  
Incision Healing Check  
Activation (Follow up Clock Starts)  
4, 12 Week Visits  
48 Weeks Follow -Up: Primary Endpoint  
8, 24, 36 Week Visits  
Explant Visit  
Incision Healing Check  
Demographics, screening exam, 
physical exam, & medical history  X          
Eligibility Determination  X X         
Informed Consent  X          
3-day Voiding Diary Reminder 
Call  X X   X X X   
3-day Voiding Diary   X X   X X X   
Return of TENS unit and diary    X        
Post Void Residual (PVR)  X          
Urinalysis  X          
Pictures Taken of Incision Site    X X X    X X 
OABq  Assessment   X X   X X X   
Patient Reported Satisfaction 
Assessment    X   X X X   
Patient Global Impression of 
Improvement    X   X X X   
Implant or Explant Procedure   X      X  
Incision Assessment     X      X 
Activation / Re -programming      X   X   
Completion of Primary Endpoints        X    
Completion of Study           X 
Subject Assessment for AEs   X X X X X X X X X 
Figure 3 -1: Summary of Study Process  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 33 of 97   
  
3-4-3 Screening for Eligibility  Procedures  
Interested adults who are known or present at the research site with UUI may be initially 
screened for inclusion in the study. Subjects’ medical records will be reviewed for 
inclusion/exclusion criteria.  
Subjects who initially qualify will be scheduled for a screening visit to assess general 
health and overactive bladder condition. Subjects will be questioned for 
inclusion/exclusion criteria in addition to medical record review. A history will be taken, 
physical exam will be performed, and general health to participate in the study will be 
further evaluated by the Investigator at the screening visit. After patients provide their 
informed consent, and urinalysis will be utilized to rule out UTI. A blood sample will be 
taken of those subjects with a history of diabetes to confirm the condition is controlled.  
3-4-4 Prior and Concomitant Therapy  
The intent of the study is to enroll subjects who are refractory to other modes of therapy, 
including behavioral therapy, pelvic floor exercises, and pharmacologic therapy.  
Subjects who are taking pharmacologic agents for overactive bladder or other agents 
that may influence urination at enrollment will be expected to discontinue those medications at least 2 weeks prior to baseline. Subjects will be expected to remain 
agent -free until the primary endpoint. The use of agents for overactive bladder will be 
reported at each follow -up visit. A complete list of prescription drugs, over -the-counter 
drugs, or dietary supplements should be taken at screening to ensure stability of 
medications that can affect  urination.  
3-4-5 Informed Consent Procedures  
The study as described in the Informed Consent Form (see Attachment 4 -5) will be 
presented to the individual for consideration at the screening visit. The individual will be 
given adequate time to have their questions answered and to carefully consider 
participation. If, after understanding the purpose, potential risks, potential benefits, and 
requirements of the study, as well as his or her rights as a research participant, the 
individu al agrees to participate as evidenced by providing written informed consent, the 
subject will be further assessed at a baseline visit. The subject should be allowed to 
take informed consent documents home for further consideration, if needed, and 
scheduled with an additional visit to complete the screening visit. The signed Informed 
Consent Form shall be included in the patient’s medical record file and noted in the screening CRF.  
3-4-6 Baseline Visit  Assessments  
At the conclusion of the Screening Visit, eligible subjects who have provided written 
informed consent will be asked to return for baseline assessments.  
Baseline assessments will include:  
1) Return of the 3- day voiding diary;  
2) OABq  questionnaire;  
3) TENS  (transcutaneous  electrical  nerve stimulation)  protocol  instructions 
provided to  subjects.  
Study staff will schedule subject’s implantation procedure to follow baseline 
assessments. All subjects who continue to meet the inclusion and exclusion criteria after baseline assessments will be enrolled in the  study.  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 34 of 97   
  
 
3-4-7 TENS Protocol  
One secondary purpose of this trial is to ascertain whether there is a relationship 
between responders to TENS and responders to eCoin therapy. Therefore, at baseline, subjects will be sent home with a TENS unit and instructions to perform 
TENS of the tibi al nerve twice daily for seven days. The electrical paradigm will be 
preset to match the electrical paradigm of eCoin (pulse width of 0.2 ms and frequency of 20 Hz), but the subject will set the amplitude of stimulation to the upper level of 
comfort. Subje cts should perform one thirty minute session in the morning and one in 
the evening for 7 days (total of 14 sessions). Subjects will be asked to complete a 
voiding diary in the last three days of the TENS protocol. This TENS protocol will 
occur after the baseline visit but before the implantation visit. Subject eligibility is not affected by response or lack of response to the TENS protocol.  
Study  staff will schedule subject’s  implantation procedure to follow collection  of three - 
day diary completed during t he last three days of the TENS protocol.  
 
3-4-8 Implantation of Subcutaneous Neuromodulation  System  
An implant procedure is to be completed following, but no later than, 28 days from the 
baseline visit. The eCoinTM system will be implanted in accordance with the procedures 
outlined in the Surgical Implant Manual set forth in Attachment 4 -2 for Manuals and  
Labels . The implant procedure is conducted as an outpatient procedure under local 
anesthesia  for subcutaneous  placement.  An incision  site healing check  will be performed 
2 weeks post implant. Subjects will be provided a minimum of 4 weeks for healing prior 
to activation of the system.  
Prior to discharge fr om the procedure, the research staff shall review study requirements 
with the subject to help ensure compliance with the follow -up schedule. Telephone 
numbers will be obtained from the participant at the time of informed consent to ensure 
the clinic is abl e to contact the subject and primary physician as needed. Patients will be 
instructed on post -procedural wound care and limitation of certain physical activities.  
Antibiotics and pain medication will be prescribed at the discretion of the investigator.  
3-4-9 eCoinTM Activation  
All subjects will return for a device activation visit four weeks after implantation. At this 
point, the follow -up visit clock will start to run (that is, the follow -up visits will be 
characterized in relationship to the date of the activat ion visit).  
The subject will be provided with a 3- day voiding diary to complete in the 7 days prior to 
the next visits (occurring 4, 8, 12, 24, 36, and 48 weeks post -activation). At least 3 days 
prior to the next visit, a member of the study staff will tel ephone subjects to remind them 
that they should begin the 3- day diary.  
 
3-4-10 Establishment of the Amplitude  Setting  
The programming technician will follow programming procedures, setting the amplitude 
according to the subject’s upper level of comfort. Subjects will be informed that they may 
periodically feel a tingling or notice a muscle twitch; but if they do, it would be transient  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 35 of 97   
  
and they should not feel anything most of the time, if at all. In particular, subjects may 
feel a motor res ponse (flexing of the big toe and/or fanning of the other toes) and 
sensory response (a radiating sensation may be felt at the sole of the foot and in the toes).  
 
3-4-11 Post Activation Follow-up Procedure  
Subjects will be followed up in visits at 4, 8, 12, 24, 36, and 48 weeks post -activation, 
with the primary analysis at 48 weeks.  
1) Overactive bladder medications should not be given at any time during the 48 
week study (unless medication is medically necessary according to the “Escape Treatment” guidelines  below).  
2) At least 3 days prior to each appointment, subjects will be responsible to complete a 3 -day voiding diary to be brought with them to each appointment.  
3) Assessments at visits 4, 8, 12, 24, 36, and 48 weeks post -activation contain the 
same procedures. They are described in the Visit Overview Section 3 -4-2. The 
8, 24, and 36 week visits will include a scheduled reprogramming to check in on 
how the patient is doing with the device settings.  
4) All other visits are also described in the Visit Overview Section 3-4-2. 
At the follow -up visit 48 weeks post -activation, the primary effectiveness endpoint will 
have been reached.  
3-4-12 Escape  Procedure  
Unless judged medically necessary, medications for overactive bladder are not allowed 
until the primary effectiveness endpoint is reached at 48 weeks post activation. Agents 
added or withdrawn  are at the discretion of the Investigator  and managing physician.  Any 
such adjustment is to be noted on the CRFs. Patients are also asked at each follow -up 
visit wheth er they have taken any medication for overactive bladder. Any answer of 
“yes” will be reported on the visit CRF and a corresponding concomitant medication 
CRF.  
 
Study Objectives  
3-5-1 Primary and Key Secondary Objectives 
3-5-1-1 Primary Effectiveness Objective  
To assess the effectiveness of eCoinTM on the proportion of subjects achieving at least a 
50% improvement in the number of urgency urinary incontinence episodes per 24 hours 
on a 3 day voiding diary after 48 weeks of therapy.  
 
3-5-1-2 Key S econdary Effectiveness Objective  
To assess the effectiveness of eCoinTM on the proportion of subjects achieving at least a 
50% improvement in the number of urgency urinary incontinence episodes per 24 hours 
on a 3 day voiding diary after 24 weeks of therap y. 
 
3-5-1-3 Primary Safety Objective  
To assess safety 52 weeks after implantation of eCoinTM. 

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 36 of 97   
  
 
3-5-1-4 Key Secondary Safety Objective  
To assess safety 28 weeks after implantation of eCoinTM. 
 
3-5-2 Secondary Objectives  
The following objectives refer to measures taken after 24 and 48 weeks of therapy.  
 
To assess the proportion of subjects achieving 75% improvement in the number of 
urgency urinary incontinence episodes per 24 hours on a 3 day voiding diary.  
 
To assess the proportion of subjects achieving 100% improvement in urgency urinary 
incontinence episodes (“Dryness”) per 24 hours on a 3 day voiding diary.  
 
To assess the reduction in the number of urgency urinary incontinence episodes per 24 
hours on a 3 day voiding diary.  
 
To assess the reduction in the number of urinary voids per 24 hours on a 3 day voiding 
diary in those subjects whose baseline shows more than 10 voids per day.  
 
To assess the reduction in the number of urgency episodes per 24 hours on a 3 day 
voiding diary.  
 
To assess the reduction in the number of nocturia episodes per 24 hours on a 3 day 
voiding diary.  
 
To assess the improvement in the patient reported quality of life utilizing the Overactive 
Bladder Symptom Quality of Life Questionnaire (OABq).  
 
To assess the improvement in patient reported overactive bladder condition utilizing the Patient Global Impression of Improvement (PGI -I) questionnaire.  
 
To assess the patient reported satisfaction with eCoinTM therapy utilizing the custom 
patient satisfaction rating survey.  
 
Rationale for the Selection of Outcome Measures and Study 
Design  
eCoinTM therapy is expected to have a positive effect on a number of symptoms of 
overactive bladder, including number of urinary urgency incontinent episodes, voiding 
volume, frequenc y, and nocturia. The primary outcome is the therapeutic effect of 
eCoin on UUI.  
Urinary incontinence is associated with substantial routine care costs and a clinically 
significant decrement in health- related quality of life that is similar to the impact of  other 
chronic medical conditions like osteoarthritis, chronic obstructive pulmonary disease, and stroke ( 31). Thus, the primary outcome focuses on an objective and significant 
symptom of overactive bladder: the number of inc ontinence episodes in a 3- day period 
in all subjects. Of the secondary outcomes, quality of life is an important measure of the  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 37 of 97   
  
overactive bladder condition because overactive bladder is a symptom -based diagnosis. 
The degree of bother caused by symptoms directly affects care seeking, treatment 
intensity, and satisfaction with treatment; however, patient reported questionnaires on 
the quality of life of incontinence patients have not been well standardized in the past.  
Selection of the t wo questionnaires is based on evidence that each, the OABq and the 
PGI-I, is a valid and reproducible self -administered measure for assessing quality of life 
in patients with urinary incontinence ( 32, 33). 
 
The Sponsor’s feasibility study for which the study device, eCoinTM, was implanted in 46 
subjects showed a benign safety profile. In particular, no infection at the implant site occurred that required explant. At the time of this writing, all subjects have been 
followed for at least six months since implantation of the study device. Given that the 
primary safety concern is infection and that all serious infections are expected to occur 
by one month after implantation, the adverse event informat ion compiled thus far is 
promising. Three serious adverse events (SAEs) have occurred: one unrelated 
pneumonia incident, one unrelated limp due to underlying bursitis of the hip present at 
screening, and one related cellulitis of the calf secondary to the ankle support suggested 
as post -operative care. See Attachment 04 -32 for additional information on safety.  
Furthermore, given the expected therapeutic similarity of percutaneous nerve stimulation of the tibial nerve to eCoin
TM stimulation of the tibial ner ve, the therapy is not expected to 
cause adverse events. Nonetheless, safety will be reported through adverse event 
reporting for the study duration.  
While an important benefit to the eCoinTM system is that delivery of therapy does not 
require the patient to operate a percutaneous device and locate the tibial nerve on a 
regular basis, it is also important to understand how well patients tolerate the device. In 
order to assess patient acceptance, a patient satisfaction grade will be documented for 
each subject at all follow- up visits.  
31. Schultz SE, Kopec JA. Impact of chronic conditions. Health Rep.  2003;14:41– 53. 
32. Wagner, T. H., et al. "Quality of life of persons with urinary incontinence: development of a new measure." Urology 47.1 (1996):  67-71. 
33. Hajebrahimi, Sakineh, et al. "Validity and reliability of the International 
Consultation on Incontinence Questionnaire- Urinary Incontinence Short Form 
and its correlation with urodynamic findings." Urology journal 9.4 (2012):  685. 
 
Risk Analysis  
3-7-1 Overview  
The eCoinTM system risk assessment (Attachment 4-14) has been completed per FDA - 
recognized Consensus Standard 5- 40: ISO 14971. The risk analysis method identifies 
each potential hazard that could result in patient harm, with action taken to reduce risk 
when the estimated risk for any potential hazard exceeds an acceptable level. The risk 
analysis for the eCoinTM system and the controller was performed early in the design 
process and has been updated throughout the process. The identified, anticipated risks 
have been mitigated so that all potential hazards are reduced to an acceptable severity 
and occurrence.  
To verify mitigation of risk, the eCoinTM system has undergone testing for safety, 
essential performance, design verification and marking per applicable parts of IEC  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 38 of 97   
  
60601- 1:2005+A1:2012(E) and ISO 14708 -1:20000(E) as well as biocompatibility testing 
to be compliant with all applicable ISO 10993 standards.  
The table in attachment 4-15 summarized the potential risks to human health and traces 
them to specific FMEA assignments and risk mitigation measures.  
3-7-1-1 Clinical Safety Data as Validation of Risks  
The eCoinTM system has been used in a successful first -in-human feasibility trial from 
2013 through 2016 for the treatment of drug -resistant hypertension in adults and in a 
human feasibility trial for the treatment of overactive bladder (OAB) in adults. The 
system parameters for the hypertension study were 2 pulses per second at a pulse width 
of 0.5 ms with amplitudes ranging from 0.5 mA to 25 mA. No adverse event related to 
stimulation therapy occurred during the two year hypertension study. Section 2- 2-2-2 is a 
summary of the safety results. In this proposed study and in the ongoing OAB study, the 
eCoinTM system parameters will be 20 pulses per second at a pulse width of 0.2 ms with 
amplitudes ranging from 0.5 mA to 15 mA. In the OAB study, one adverse event  related 
to stimulation occurred for which the subject experienced moderate pain during the 
intermittent stimulation (i.e., 30 minutes every other day). This was the first subject 
programmed with the device in the U.S. and it was learned that the subject r equired 
more time for healing in order to provide better sensory feedback and to set the device to the upper level of comfort. The adverse event was resolved with a  reprogramming.  
The proposed system parameters match those utilized by many percutaneous tibial 
nerve stimulation studies for which no stimulation- related adverse event has been 
reported (3, 13, 17) and the same parameters used by FDA -cleared devices (K132561) 
that also stimulate the tibial nerve for treatment of overactive bladder. According to the 
American Urological Association’s guideline on the diagnosis and treatment of 
overactive bladder ( 34), percutaneous tibial nerve stimulation carried minor adverse 
events in reviewed studies. The most frequently reported events were painful sensation 
during stimulation that did not interfere with treatment and minor bleeding at the insertion 
site. In the panel’s view, benefits outweigh risks and burdens for the use of 
percutaneous tibial nerve stimulation in the thoughtfull y-selected and counseled patient 
who is highly motivated to make the office visits required for repeated percutaneous administration of tibial nerve stimulation.  
34. Gormley A, Lightner D, Burgio K, Chai T, Clemens JQ, Culkin D, Das A, Foster 
HE, Scarpero HM, Tessier C, Vasavada SP, Diagnosis and Treatment of 
Overactive Bladder (Non -neurogenic) in Adults: AUA/SUFU Guideline. American 
Urological Association Education and Research 
https://www.auanet.org/education/guidelines/overactive- bladder.cfm  
3-7-2 Description of Patient Population  
The eCoinTM system is indicated for the treatment of patients having UUI. For inclusion, 
subjects must meet all inclusion criteria and none of the exclusion criteria. For more 
information about inclusion criteria, see Inclusion Criteria 3 -3-2-2-1. 
Patients with overactive bladder, including those with the symptom of urgency urinary 
incontinence, have a clinically and statistically significant lower quality of life, lower 
depression status, and poorer quality of sleep than other people ( 35). Overactive 
bladder causes additional health problems including increased risk of falls and fractures 
(presumably from nocturia in the elderly), urinary tract and skin infections, sleep 
disturbances and depression ( 36). Most studies investigating the cost of overactive 
bladder focus on the economic burden of overactive bladder, showing a total cost to the  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 39 of 97   
  
US healthcare system of $26.3B a year ( 37). Patients with refractory urgency urinary 
incontinence are those who are not achieving adequate control of incontinence 
symptoms through available modes of therapy. Such modes include behavioral therapy, 
pelvic floor exercises, and pharmacological therapy. Refractory patients may be eligible 
for inclusion in this study.  
35. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P,Herzog AR, Corey R, Hunt 
TL and Wein AJ, Prevalence and burden of overactive bladder in the United 
States (NOBLE Study), World J Urol (2003) 20:  327–336. 
36. Brown JS, McGhan WF, and Chokroverty S, Comorbidities Associated With 
Overactive Bladder, The American Journal of Managed Care, Vol. 6, No. 11, 
SUP (2000),  S574- S579.  
37. Wagner TH, Hu TW. Economic costs of urinary incontinence in 1995. Urology 
1998;51:355 -361. 
3-7-3 Justification for Investigation 
3-7-3-1 Potential Benefits of Treatment  
According to the American Urological Association (AUA) and its guideline for diagnosis  
and treatment of overactive bladder, an AUA Panel interpreted the available 
percutaneous tibial nerve stimulation data to indicate that percutaneous tibial nerve stimulation can benefit a carefully selected group of patients characterized by 
moderately sev ere baseline incontinence and frequency and willingness to comply with 
regular return visits for administration of the percutaneous therapy. The Grade C 
evidence supports a potential benefit of tibial nerve stimulation in overactive bladder 
patients of improvements to incontinence episodes, voiding volume, quality of life, 
frequency, and nocturia. Furthermore, in a study by Finazzi -Agro et al., patients 
matching some features of the population for the proposed study —females with 
detrusor overactivity incont inence—showed statistically and clinically significant 
improvements in mean incontinence episodes per 3 days, mean voids per day, mean 
voided volume, and mean QoL score (17). Thus, potential benefits of tibial nerve 
stimulation by eCoin
TM include improvements to the number of incontinence episodes, 
voiding volume, frequency, and quality of life.  
This current study is primarily concerned with UUI.  
3-7-4 Additional Safety Profile Information 
3-7-4-1 Description of  Procedure  
eCoinTM is placed into a subcutaneous pocket in the lower leg. The anatomical 
structures involved in the implantation procedure are skin, subcutaneous tissue, and 
fascia. The eCoinTM sits above the fascia so the deeper structures are not affected. No 
significant nerves or vessels, other than subcutaneous veins which are of minimal significance, are present in the subcutaneous pocket. eCoin
TM is placed about 3 mm 
above its target nerve (tibial nerve).  
Similar to other inert prosthetic devices, a fibrous capsule is e xpected to form around the 
eCoinTM system. This capsule stabilizes the implant at its desired location and 
compartmentalizes it from the surrounding tissues (skin, subcutaneous fat, and fascia).  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 40 of 97   
  
3-7-4-2 Therapeutic or Stimulation Risks 
Although stim ulation could briefly exceed a comfortable level during the activation 
procedure, no serious complication from tibial nerve stimulation is known or anticipated. 
Stimulation pulses are charge balanced at a charge density level known to be safe for 
neuromodulation with platinum electrodes (≤ 100 µC/cm2). If stimulation intensity above 
the subject’s comfort level is reached during programming in the clinic, the subject may 
feel discomfort or pain until the stimulation level is turned down. The subject may 
experience a muscle twitch related to stimulation of the tibial nerve. Discomfort or 
muscle twitch is managed through optimal setting of stimulation amplitude to subject 
comfort levels. Adjustments to stimulation levels are made only in the clinic where the 
patient response can be monitored and adjustments made as needed.  
The energy discharge of the eCoinTM battery is such that no harm will arise from heating 
due to a battery short. Direct shorting of the 75mAh battery delivers less than 200 mW or 
20 mW/cm2 of heat from the device surface to tissue. This ensures a safe level of tissue 
heating (less than 2 degrees Centigrade) in a worst case direct short failure condition.  
3-7-4-3 Risks of eCoinTM Implantation 
The most probable risks associated with eCoinTM implantation include the following: 
ecchymosis, erythema, and incisional pain at the implant site; intermittent paresthesias 
of the toes, foot, or lower leg; and other wound healing complications. Other risks that 
are categorized as uncommon or rare are reported below:  
UNCOMMON  
• Hematoma at the incision site 
• Implant site infection that leads to device explant  
• Persistent implant site  pain 
• Severe pain during or shortly after the  procedure  
• Persistent wound healing complications lasting beyond 8 weeks post  implant  
• Persistent stimulation discomfort 
RARE  
• Wound dehiscence  
• Allergic reactions to local  anesthesia  
• Inflammation of nearby  tendons  
• Localized neuritis  
• Surgical injury to adjacent nerves, vessels or  tendons  
• Allergic reaction to implanted materials  
• Implant device failure leading to explant  
• Implant device extrusion 
• Implant device migration requiring explant or  revision 
• Implant device inversion  
Device -related risks of the eCoinTM system can be deduced from the 50 year field of 
neuromodulation. The primary risks of im portance are infection and lead- related 
problems (e.g., leadwire break or migration). For the leadless eCoinTM system, lead-  
related problems are not relevant. Reasonable estimation of the rate of infection can be 
based upon other neuromodulation devices, the sponsor’s feasibility study testing 
eCoinTM for hypertension, and the sponsor’s feasibility study testing eCoinTM for OAB. 
Infection can be mitigated through surgical training, adequate manufacturing controls, and adequate after -care instructions. Infe ction can be resolved through antibiotics 
generally and, in a worst case scenario, explantation of eCoin
TM. 
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 41 of 97   
  
If needed, explantation of the eCoinTM device can be performed easily through simple 
opening of the capsule and removal of the device. If the capsule itself has a significant 
problem such as deep infection or dense scar tissue causing significant discomfort, then 
the capsule might require surgical excision, a procedure known as capsulectomy.  
In the ongoing clinical study of eCoinTM for OAB conducted under an IDE, no patient 
required explant due to infection. One cellulitis of the calf secondary to the ankle wrap 
occurred where the patient chose to have the device explanted prior to activation of the 
device. The aforementioned safet y data are current as of the date of this writing at which 
time all patients have been followed at least six months from implantation. See Attachment 04- 28 for a table on reported related adverse events. In the OUS clinical 
study of eCoin
TM for hypertension, the proportion of infection requiring explant, on a per 
patient basis was approximately 4.2%. See Subsection 2-2-2-1 and 2-2-2-2 for details on 
the adverse events that occurred during both studies.  
The eCoinTM utilizes established biocompatible materials and manufacturing processes 
that are typical of implantable neurostimulators (titanium hermetic enclosure, silicone 
elastomer insulation coating (MED -4870) and with platinum stimulating electrodes).  
3-7-5 Standards Conformance Demonstrating Safety  
The eCoinTM system has been developed under design control in accordance with QSR 
21 820.30 and ISO 13485.  
3-7-5-1 Risk Management  
Risk m anagement conforms to ISO 14971:2012(E). A Risk Assessment has been 
completed for the SNS system based on Use, Design and Process FMEAs (See Risk Assessment Report 110- 1493 in attachment 4 -14). 
3-7-5-2 Development Process and Design Verification  Testing  
Safety, Essential Performance, Design Verification and Marking have been completed 
per applicable parts of IEC 60601- 1:2005+A1:2012(E) in compliance with active 
implantable medical devices ISO 14708- 1:2000(E) and software life cycles per IEC 
62304:2006. Attachment 4 -16 is a summary of design verification testing results.  
3-7-5-3 Biological  Evaluation  
The eCoinTM system is an active implantable device for long term patient contact 
duration (>30 days). The eCoinTM system has been subject to biocompatibility testing in 
accordance with the ISO 10993 series of standards. Biocompatibility compendiums 
were obtained from the suppliers of all materials to confirm that the supplier is also 
compliant with ISO 10993 requirements. The testing summarized in Table 3- 2 was 
performed on sterile devices representing the final product using Good Laboratory Practices. Test Article Preparation was performed in accordance with ISO 10993- 12. 
Based on the results of the in vitro testing, the eCoin
TM Subcutaneous Neuromodulation 
System is safe and effective as an implant for the intended use.  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 42 of 97   
  
Standard  Title Result  
ISO 10993 -3:2003  Biological evaluation of medical devices - Part 3:   
 Tests for genotoxicity, carcinogenicity and   
 reproductive toxicity.   
 ISO Bacterial Mutagenicity Test – Ames Assay  Pass  
 Mouse Lymphoma Assay  Pass  
ISO 10993 -5:2009  Biological evaluation of medical devices - Part 5:   
 Tests for in vitro cytotoxicity.   
 Cytotoxicity – Elution Test - MEM Extract  Pass  
ISO 10993 -6:2007  Subcutaneous Implantation Test – 90 days  Pass  
 Systemic Toxicity Study of “SNS Biocompatibility  Pass  
 Test Device” in Sprague Dawley Rats following   
 Subcutaneous Implantation for 90 Days   
ISO 10993 -7:2008  Biological evaluation of medical devices -- Part 7:  Pass  
/AC:2009  Ethylene oxide sterilization residuals.   
ISO 10993 -10:2010  Biological evaluation of medical devices - Part 10:   
 Tests for irritation and delayed -type hypersensitivity.   
 Intracutaneous (Intradermal) Reactivity Test in New  Pass  
 Zealand White Rabbits   
 Maximization Test for Delayed- Type Hypersensitivity 
in Hartley Guinea Pigs  Pass  
ISO 10993 -11:2006  Biological evaluation of medical devices - Part 11:   
 Tests for systemic toxicity   
 Acute Systemic Toxicity Test in CD -1 Mice Pass  
 Pyrogen Test in New Zealand White Rabbits  Pass  
Table 3- 2: ISO 10993 Biocompatibility Testing  
 
3-7-5-4 Sterilization and Sterile  Packaging  
The ethylene oxide sterilization process for the eCoinTM device has been developed, 
validated and is controlled per ISO 11135:2007 (see attachment 4 -17). The sterile 
package sealing process and shelf life were developed and validated per ISO 11607 
(see attachment 4 -18). 
 
Description of the Device  
Valencia Technologies eCoinTM therapy for urgency urinary incontinence provides 
electrical stimulation to the tibial nerve from a small self -contained implant placed in the 
subcutaneous space over the tibial nerve in the lower leg. Subjects receive the implant 
unilaterally in a simple procedure under local anesthetic.  
To stimulate the tibial nerve with the eCoinTM implant, the same parameters as 
previously demonstrated in animal, in human studies, and in the eCoinTM for OAB 
feasibility trial are applied. The stimulation rate is 20 pulses per second (pps) at a pulse 
width of 0.2 ms. The stimulation pulse amplitude is  adjusted to the highest comfortable 
level for the subject with an external controller. After activation, the implant  automatically  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 43 of 97   
  
provides 30 minute stimulation sessions according to a fixed treatment interval schedule. 
In between sessions , the amplitude can be adjusted or automatic therapy can be turned 
off. The device contains a battery that will typically operate for 2 to 4 years before the device requires replacement.  
3-8-1 Components  
1) eCoinTM Implant – The implant is a coin- sized leadless battery powered device 23 
mm in diameter and 3.2 mm thick. The electronics and battery are hermetically enclosed in a titanium case. The materials in direct contact with tissue are the 
platinum electrodes, and the silicone elastomer jacket (NuSil MED 4870) that covers 
the titanium housing. Each implant receives a unique traceable serial number including labeling to place in recipient medical  records.  
2) External Controller –  The external controller programs the device via a magnetic field 
using a custom access code secured wireless  protocol.  
 
3-8-2 Stimulation Settings/Parameters 
Amplitude Range: 0.5 up to 15 mA  (programmable) 
Rate: 20 pulses per second (fixed)  
Pulse Width: 0.2 ms (fixed)  
Treatment Duration: 30 Minutes (fixed)  
Treatment Interval:3 days for the first 18 weeks (42 sessions) and every 4 days 
thereafter (fixed)  
3-8-3 Implant  Procedure  
Subcutaneous implantation of the eCoinTM is done under local anesthesia. The most 
prominent point of the medial malleolus will be palpated and marked. With the foot 
positioned at a 90 -degree angle, a second marking is made 3 cm posterior to the medial 
malleolus marking. The implantation target location is found 3 cm cephalad to this 
second point along a line parallel to the posterior margin of the calcaneal tendon.  
Continuing on this line, the incision is made 8 mm cephalad to the target implantation 
site. The incision is made to the depth of the fascia with a width slightly smaller than that 
of the eCoinTM. Then, the eCoinTM is slid on top of the fascia until it reaches the  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 44 of 97   
  
implantation site. The incision is then closed and dressed. See Attachment 4 -2 for a 
complete surgical implant manual.  
 
 
 
3-8-4 Activation of eCoinTM System  
After a 4 week period of implant healing, the eCoinTM devices are activated with the 
stimulation amplitude set to the subject’s upper most comfortable level. Once activated, 
the eCoinTM applies a 30 minute session of neuromodulation therapy at the programmed 
amplitude every 3 days for a 18 week period and then every 4 days thereafter. All 
subjects are activated and the schedule of therapeutic sessions is automated as 
discussed.  
3-8-5 Subject Compliance Monitoring  
eCoinTM Therapy: Neuromodulation therapy is provided automatically by the implant 
system and has no c ompliance requirements.  
Drug Therapy: Subjects will be asked whether they are taking an overactive bladder 
medication through the primary endpoint to confirm that subjects are free of overactive 
bladder medication.  
Data: Compliance with voiding diaries is established through review by the clinical study 
coordinator at each center.  
Appointment Compliance: Clinics’ designated study coordinators will ensure subjects 
are compliant with study appointments within the scheduling parameters outlined in t he 
Visit Overview described in Section 3 -4-2. 

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 45 of 97   
  
3-8-6 Safety and Adverse  Events  
3-8-6-1 Medical Monitoring  
The study will be approved by a study -wide independent ethical committee or 
institutional review board. The participating Investigators will monitor t he subjects 
medically.  
3-8-6-2 Definitions of Adverse  Events  
Adverse Event (AE): Any untoward medical occurrence in a study participant whether 
or not there may be a causal relationship with this treatment / intervention. This can 
include (but is not limited to) worsening of subject’s overactive bladder condition and/or 
occurrence of serious sudden events.  
System and Procedure Related Adverse Event: Any adverse event related to the 
device or placement procedure. This can include risks associated with t he procedure, 
implant site or stimulation such as infection, or unexpected related adverse events that 
occur in relation to implant placement, tibial nerve stimulation or device failure. The 
Sponsor maintains a list of expected adverse events and is responsible for determining 
expectedness.  
3-8-6-3 Classification of  Events  
Relationship  
YES-  related: The event has a reasonable possibility of a causal relationship to the 
administration of tibial nerve stimulation (procedure, device, or stimulation) and no other 
etiology explains the event.  
NO- not related: The event is independent of tibial nerve stimulation (procedure, device, 
or stimulation) and/or the event appears to be explained by another etiology.  
 
Severity  
Mild: Transient or mild discomfort (<48 hours); no medical intervention/therapy required 
and does not interfere with the subject’s daily activities.  
Moderate : Some limitation in activity; some assistance may be needed; no or minimal 
medical intervention/therapy required.  
Severe : Marked limitation in act ivity; interrupts participant’s usual daily activity and may 
require medical intervention/therapy; hospitalization possible.  
Serious: Results in death during the study period; is life -threatening; requires 
hospitalization or prolongation of existing hospit alization; results in persistent or 
significant disability or incapacity; results in a congenital anomaly or birth defect; 
requires medical or surgical intervention to preclude permanent impairment of a body 
function or to prevent permanent damage to a bod y structure, where the device is 
suspected to cause such intervention; other important medical events not captured by 
the other categories where the event may jeopardize the patient and may require 
medical or surgical intervention to prevent one of the other outcomes.  
 
Expectedness  
Expected: Any adverse reaction whose nature and intensity are consistent with that 
described under risk assessment.  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 46 of 97   
  
Unexpected: Any adverse reaction not included under risk assessment.  
3-8-6-4 Recording of Adverse  Events 
Expected device -related AEs will be recorded on case report forms as shown in 
Attachment 4-9, which are used at each visit. Unexpected or unrelated AEs or any 
requiring medical attention will be reported on CRFs and further recorded on AE forms. 
Subjects will be requested to report adverse urologic events that are inconsistent with 
their normal medical condition that occur in between visits to the study coordinator or 
medical staff who will record on AE forms. All adver se events will need to be evaluated 
and assigned by a medical reviewer on or designated by the Data and Safety Monitoring Board (DSMB) with regards to:  
1) Relatedness or causality to the study  device  
2) Severity  
3) Expectedness  
4) Action taken  
The Sponsor is responsible for determining if an adverse event is unexpected. If 
expectedness is assessed by a medical reviewer as unexpected, the Sponsor will be 
notified and will evaluate and assign a final determination that may or may not result in a 
requirement to r eport expeditiously to regulators, IRBs, or both.  
 
At each contact with the subject, the Investigator will obtain information on AEs by 
specific questioning and examination. In the CRF for visits, if an event is reported, the 
AE checkbox will be selected. This selection will trigger a separate form to be filled out 
that records the following information:  
1. Subject  Number  
2. Adverse Event  (AE) 
3. Date of AE  onset  
4. Date of AE  cessation  
5. Severity  
6. Expectedness  
7. Causality  
8. Was the patient hospitalized? If yes, provide  dates.  
9. Will the patient continue with treatment, and will any be missed?  
10. Did the patient add or change any other associated medication and what 
were the  changes/additions? 
11. Was any other action taken? 
When an AE has been recorded, the PI or sub- PI for the study must sign and approve 
the assessment on the Sponsor -provided form. The Study monitor will keep track of all 
reported AEs. A sample of the AE report form is in Attachment 4 -9. 
3-8-6-5 Reporting Procedures  
For Serious Adverse Events (SAEs) or suspected Unanticipated Adverse Device Effects 
(UADEs), the Study Coordinator, the PI, and the Sponsor will be alerted. The timeline 
for medical review and assessment is 24 hours for SAEs and 7 days from subject 
reporting of non- seriou s unexpected device related AEs. For suspected UADEs, the 
Sponsor will promptly provide an expectedness determination. The Investigator  must  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 47 of 97   
  
promptly inform the Ethics Board or IRB of SAEs or determined UADEs per local 
reporting requirements.  
 
The SAE form provided by the Sponsor should be completed and signed by the 
Investigator or physician sub- investigator and faxed or emailed to the Sponsor per the 
instructions on the form. The entire SAE form needs to be completed, if possibl e, to 
make available in a timely manner complete relevant information thus limiting requests 
for additional information. Each SAE reported on an SAE form must also be reported in 
the adverse event section of the CRF.  
 
These events will be reported by the S ponsor as appropriate to the regulatory authorities 
according to relevant jurisdictional medical device regulations. The Investigator will 
receive notification of these events across all study centers from the Sponsor.  
3-8-6-6 Adverse Event Reporting Period  
Adverse event information will be collected throughout the entire study between 
Informed Consent and final follow -up. If the patient presents to the Investigator after the 
study period and a device- related AE is suspected, the AE should be reported to the 
Sponsor using the post -study AE form provided by the Sponsor. Post -study adverse 
events should be reported to the Sponsor after the study period if they are:  
1) AEs that are device -related resulting in a revision surgery or explant (explant for 
reasons other than for normal end of life –  e.g. battery depletion) for which the 
patient presents to the  PI. 
2) AEs that occur during or related to an explant procedure performed at the normal device end of  life. 
3-8-7 Subject Withdrawal & Termination  
This section describes reasons for withdrawal of subjects and termination of the study. A Statistical Analysis Plan (SAP) will describe in detail the methods for handling data from 
subjects who withdraw, or are withdrawn, early from the study.  
3-8-7-1 Early Withdrawal of  Subjects  
Subjects may voluntarily withdraw from the study for any reason at any time. They may 
be considered withdrawn if they state an intention to withdraw, fail to return for visits, or 
become lost to follow -up for any reason. The devices must be recommended to be 
explanted if the subject is withdrawn.  
3-8-7-2 Terminating Subject  Participation  
A subject’s continued participation in the study must be terminated if in the Investigator’s opinion, continued participation would be detrimental to the subject’s well -being. If t he 
subject is unwilling or unable to attend all remaining follow -up visits, or if subject is lost to 
follow- up, the subject’s continued participation must be terminated. If the subject is 
explanted for any reason, subject participation must be terminated.  
The subject’s eCoin
TM system must be recommended to be explanted if the subject’s 
participation is terminated.  
3-8-7-3 Withdrawal/Termination  Procedures  
If premature withdrawal occurs for any reason, the Investigator must make every effort to 
determine the primary  reason for a subject’s premature withdrawal from the study and 
record this information on the Case Report Form for reporting to the Sponsor.  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 48 of 97   
  
Subjects enrolled in the study will not be replaced if they withdraw or are terminated from 
the study after device activation. Provisions for device explantation will be arranged.  
3-8-7-4 Early Study  Termination 
The study can be terminated at any time for any reason by Valencia Technologies. 
Should this be necessary, the subjects should be seen as soon as possi ble and treated 
as described in the early withdrawal section for a prematurely withdrawn subject. The 
Investigator may be informed of additional procedures to be followed in order to ensure 
that adequate consideration is given to the protection of the subj ects’ interests. The 
Investigator will be responsible for informing the IRB of the early termination of the trial. 
If required, provisions for the explant of the eCoinTM system will be arranged.  
3-8-7-5 Data Collection and Follow -up for Withdrawn Subjects  
Subjects  who are not implanted with the eCoin study device will not be followed after 
termination or withdrawal from the study.  
3-8-8 COVID-19 Related Delayed Explantation 
Subjects who do not or did not consent to extended follow up may have an explant  well 
beyond the final study visit window because of COVID -19 considerations.  However, the 
database may be locked through the 48 week final study visit following complete 
monitoring.  Subjects who do not or did not consent to extended follow up will not undergo 
study procedures beyond those originally consented but will continue to be followed for 
adverse events and complaints until explantation is performed and healing is observed.  
This will be done under the extension portion of this protocol.  
3-8-9 Data and Safety Monitoring Board  
A Data and Safety Monitoring Board of at least three members will review data including 
a quarterly report of Adverse Events. This DSMB will meet by telephone monthly until all 
subjects reach one month post -implantation and at least quarterly until all subjects reach 
52 weeks post -implantation to review aggregate and individual subject data related to 
safety, data integrity, and overall conduct of the trial. The DSMB will be responsible for 
reviewing adverse events. The DSMB will provide recommendations to continue or 
terminate the trial depending upon this rev iew. A DSMB charter is set forth in a DSMB 
Charter document (see 4 -10). 
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 49 of 97   
  
Data Analysis Plan  
3-9-1 Data Collection  
All study data will be recorded onto Case Report Forms (CRFs) provided by Valencia 
Technologies. All C RFs will be completed using de- identified data. The CRFs will also 
serve as the source documents for the study. Valencia will enter the recorded data 
from CRFs into an Electronic Data Capture (EDC) system supported by Company eSOCDAT. eSOCDAT’s system main tains the integrity of patient privacy using a 
secure server and patient information is still de- identified, using patient numbers only.  
CRF completion may be delegated to other study personnel, but the Investigator 
remains responsible for the accuracy and  integrity of all data entered on CRFs. CRFs 
will be completed and sent to the designated representative for Valencia Technologies as directed, in an expedited fashion. All CRFs will be completed by 
study personnel only. Valencia or its designee will work with participating sites to 
secure data clarification and to obtain additional relevant medical documentation on 
participants enrolled into this trial.  
CRFs for the study  include:  
1) Screening 
2) Baseline  
3) Implantation (Part 1 and Part  2) 
4) Implant Healing Check  
5) eCoin
TM Programming  
6) Follow -up (4, 8, 12, 24, 36, and 48 weeks  post-activation)  
7) Adverse  Event  
8) Study  Termination 
9) Protocol  Deviation  
10) Explantation 
11) Explantation Healing Check  
12) Unplanned Visit  
3-9-2 Interim Monitoring  
All clinical sites will be monitored periodically by Valencia Technologies or its 
designated representatives. Telephone contacts and site visits will be made 
throughout the course of the study.  
During site visits, the monitor will review participant records,  device accountability 
and storage, and general study procedures. The monitor will also discuss any 
problems with the Investigator. Monitors will audit data collected on CRFs and verify 
data against source documentation in accordance with the Clinical Monitoring Plan in 
Attachment 4.22. Monitors will confirm that written Informed Consent was properly 
obtained prior to enrollment of each participant. Any evident pattern  of non - 

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 50 of 97   
  
compliance will be addressed with the Investigator. If appropriate corrective actions 
are not subsequently undertaken, Valencia reserves the right to suspend enrollment at 
the site and/or withdraw the site from the study.  
At the close of the study at a res earch site, the clinical monitor will make a final on-   
site visit to collect all outstanding study data documents, ensure that the Investigator's 
files are accurate and complete, review record retention requirements with the 
Investigator, make a final acc ounting of all study supplies shipped to the Investigator, 
provide for appropriate disposition of any remaining supplies, and ensure that all 
applicable requirements are met for the study.  
COVID -19 Considerations  
Due to the COVID -19 pandemic, monitors may not be able to travel to the 
investigational site to complete onsite monitoring of data. As an alternative, monitors are to complete remote monitoring visits. This involves scanning source and CRFs by site personnel to the monitor and verifying all documentation in accordance with the 
Clinical Monitoring Plan in Attachment 4.22. Due to personnel lay offs or temporary 
site closures, some data may not be able to be accessed, or monitoring may be 
delayed. Any deviations from the monitoring plan will be documented in the 
corresponding monitoring reports.  
 
 
3-9-3 Analysis Plan Summary  
This prospective, multicenter, single- arm study is designed to assess the safety and 
effectiveness of the eCoinTM tibial nerve neuromodulation system for the treatment of 
urgency urinary  incontinence. Up to 135 subjects, with a target of 120 subjects, from 
approximately 20 different centers will be enrolled.  
The remainder  of this section briefly  describes  the analyses  planned for this study.  A full 
Statistical Analysis Plan (SAP) will be prepared. The SAP will include more technical and detailed elaboration of the statistical analyses. If there are minor differences 
between the analyses described in this section and the analyses in the SAP, the analyses  in the SAP will prevail.  A change  to the data analysis  methods  described in the 
protocol will require a protocol amendment only if it alters a principal feature of the 
protocol.  
3-9-3-1 Rationale for Design Choice  
Safety  
The feasibility trial of eCoinTM treating OAB with UUI in the US and New Zealand was 
conducted at 7 centers with 46 subjects implanted. The results described in Section 2 -2- 
2-2 show a minimally invasive procedure under local anesthesia and minor wound 
healing problems.  
 
Under this protocol, eCoinTM will be tested to confirm that eCoinTM has a similar benign 
safety profile at more centers (20) with more (135) implanted subjects.  
 
 
Effectiveness  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 51 of 97   
 This open label, single- arm study will evaluate eCoinTM’s effectiveness in reducing 
episodes of urgency urinary incontinence. The proportion of subjects achieving at least a 
50% reduction from baseline in the number of urgency urinary incontinence episodes  will 
be reported.  
 
Valencia considered a controlled trial against an approved drug or placebo. Such a trial 
would be very difficult to blind. Recruitment to a trial comparing eCoinTM to Interstim 
would be difficult because many people are unwilling to use  Interstim.  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 52 of 97   
  
3-9-3-2 Analysis Sets  
Effectiveness analyses will be generated for all analysis populations described below. 
Safety data will be reported on all enrolled subjects who undergo a procedure for 
implantation of the study device 
1) Intent -to-Treat (ITT): All enrolled subjects who undergo a procedure for 
implantation of eCoinTM. This is the primary analysis population for the safety  and 
effectiveness analyses.  
2) Modified Intent -to-Treat (mITT). All subjects in the ITT population meeting all 
eligibility  criteria.  
3) OAB drug -free. All subjects in the mITT population who took no medication for 
OAB during the study  period.  
4) Per-protocol (PP): The subset of OAB drug- free subjects excluding all subjects 
with any other major protocol violation. The SAP will define major protocol 
deviations.  
5) Responders: Subjects who respond to treatment, defined as those who achieve at least a 50% reduction in the number of urgency urinary incontinence episodes 
from baseline to 48 weeks  post-activation.  
6) TENS Cohort Analysis (TNS): The subset of ITT subjects less any patients who 
do not respond to the TENS protocol where response is defined as a 30% 
reduction in urgency urinary incontinence episodes or a 30% reduction in 
urgency episodes from baseline afte r 7 days of  TENS.  
7) Long- term Completers: All mITT subjects who attend a particular visit. This is the 
primary analysis population for the effectiveness and safety analyses performed 
at 2 and 3 years post -activation for subjects who consent to extended  follow-up. 
 
The SAP may define additional analysis sets of subjects.  
 
 
3-9-3-3 Planned analyses  
Primary Effectiveness Outcome  
 
The primary effectiveness outcome is achieving at least a 50% reduction from baseline 
in the number of urgency urinary incontinence episodes per 24 hours on a 3 day voiding 
diary after 48 weeks of eCoinTM tibial nerve stimulation.  
 
The proportion of respon ders along with its 2- sided 95% exact Clopper -Pearson 
confidence interval will be summarized after 48 weeks of therapy.  
 
 
Key Secondary Effectiveness Outcome  
 
The key secondary effectiveness outcome is achieving at least a 50% reduction from 
baseline in t he number of urgency urinary incontinence episodes per 24 hours on a 3 
day voiding diary after 24 weeks of eCoinTM tibial nerve stimulation.  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 53 of 97   
  
The proportion of subjects with at least 50% reduction from baseline along with its 2 - 
sided 95% exact Clopper -Pearson confidence interval will be summarized after 24 
weeks of therapy.  
 
 
Primary Safety Outcome 
 
The primary safety outcome is device- related adverse events from implantation to 52 
weeks after implantation of eCoinTM. 
 
All device -related adverse events up to 52 weeks after implantation of eCoinTM will be 
summarized by preferred term. Tabulations of these data will include the number of 
subjects exposed and the number of subjects with at least one device -related adverse 
event.  
 
 
Key Secondary Safety Outcome  
 
The key secondary safety outcome is device- related adverse events 28 weeks after 
implantation of eCoinTM. 
 
All device -related adverse events up to 28 weeks after implantation of eCoinTM will be 
summarized by preferred term. Tabulations of these data will include the number of subjects exposed and the number of subjects with at least one device -related adverse 
event.  
 
 
Secondary Outcomes  
 
The secondary outcomes listed in this section are based on data after 24 and 48 weeks 
from activation (28 and 52 weeks after implantation). These outcomes, which are for 
descriptive purposes, will not be formally analyzed stati stically. The SAP will describe in 
detail analyses of the secondary outcomes.  
 
• Achieving 75% improvement in the number of urgency urinary incontinence 
episodes per 24 hours on a 3 day voiding diary.  
 
• Achieving 100% improvement in urgency urinary incontinence episodes 
(“Dryness”) per 24 hours on a 3 day voiding diary.  
 
• Reduction from baseline in the number of urgency urinary incontinence  episodes 
per 24 hours on a 3 day voiding diary.  
 
• Reduction from baseline in the number of urinary voids per 24 hours on a 3 day 
voiding diary in those subjects whose baseline shows more than 10 voids per 
day. 
 
• Reduction from baseline in the number of urgency episodes per 24 hours on a 3 
day voiding diary.  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 54 of 97   
  
 
• Reduction from baseline in the number of nocturia epis odes per 24 hours on a 3 
day voiding diary.  
 
• Change from baseline in patient -reported quality of life utilizing the Overactive 
Bladder Symptom Quality of Life Questionnaire  (OABq).  
 
• Change from baseline in patient -reported overactive bladder condition utilizing 
the Patient Global Impression of Improvement (PGI -I) questionnaire.  
 
• Patient -reported satisfaction with eCoinTM therapy utilizing the custom patient 
satisfaction rating survey.  
 
3-9-3-4 Exploratory Subgroup Analyses  
Subjects who respond to treatment (i.e., who achieve at least a 50% reduction from 
baseline to 48 weeks post -activation in the number of urgency urinary incontinence 
episodes per 24 hours on a 3 day voiding diary) will be compared to non- responders in 
terms of baseline characteristics, dem ographics, and effectiveness endpoints.  
3-9-4 Sample Size  Consideration  
The study is designed to estimate the proportion of subjects achieving a clinically 
meaningful level of improvement, defined as subjects with at least a 50% reduction from 
baseline in the nu mber of urgency urinary incontinence episodes after 48 weeks of 
therapy. Up to 135 subjects will be enrolled, with a target enrollment of 120 subjects. The 
performance goal for this study is to show at least a 40% response rate after 48 weeks of 
therapy. The primary efficacy analysis will be performed by testing the null hypothesis H o 
that the percentage responding is less than or equal to 40% against the alternative 
hypothesis H 1 that the percentage is greater than 40%. The test will be performed at an 
overall 1 -sided 2.5% level of significance.  
H0: the true percentage responding ≤ 40% 
H1: the true percentage responding > 40%  
 
The study will be considered successful if the lower bound of the 2-sided 95% exact 
Clopper -Pearson confidence interval for the perc entage responding is greater than 
40%.  
 
The study is designed to detect an improvement in the percentage responding compared with a historical percentage of 40%. The study will enroll a target of 120 
subjects to ensure collection of sufficient efficacy and safety data. The study will 
have 80% power to detect a 13% increase in the percentage responding from 40% 
to 53%, 90% power to detect a 15% increase from 40% to 55%, and 95% power to detect a 17% increase from 40% to 57%, at 1-sided 2.5% significance level. 
Calculations used PASS 2019, v19.0.2.  
 
The justification for the performance goal of 40% comes from published literature for the approved and thought to be clinically significant third-line device for UUI —a fully - 
implanted neuromodulation device called “Interstim”. Note that given this study’s 
sample size, to observe 50% of patients improve by at least 50% in their urgency 
urinary incontinence symptoms as measured at the 12 month point, the lower bound  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 55 of 97   
  
of a 95% confidence interval is 40%. The published literature on sacral 
neuromodulation supports the clinical significance of a 40% responder rate. From 
the observed modified ITT responder rate in the well -cited ROSETTA study (38), it 
can be deduced that there is a lower bound of 41% for those with diaries for all 6 months, and 43% for those with at least 4 months of diaries. Importantly, these 
results are not ITT. In the review of the Insite study (39), the Sponsor derived an ITT 
responder rate of 59% f rom the available as -treated analyses. From this ITT 
deduction, the lower bound of the 95% confidence interval is 44%. Both of these 
published data were measured at 6 months whereas the endpoint in the study 
contemplated by this IDE is 12 months. If either  study was extended to 12 months, 
the number of subjects reporting would likely be even smaller, resulting in a lower 
bound at or below 40%.  
 
38. Amundsen CL, Richter HE, Menefee SA, et al. “OnabotulinumtoxinA vs Sacral 
Neuromodulation on Refractory Urgency Ur inary Incontinence in Women: A 
Randomized Clinical Trial.” JAMA. (2016);  316(13):1366– 1374.  
39. Siegel, Steven, et al. "Results of a prospective, randomized, multicenter study 
evaluating sacral neuromodulation with InterStim therapy compared to standard 
medical therapy at 6 ‐months in subjects with mild symptoms of overactive 
bladder." Neurourology and Urodynamics 34.3 (2015):  224-230. 
 
3-9-5 Calculation of Effectiveness Variables  
Change in Urgency Urinary Incontinent Episodes: Urgency Urinary Incontinent 
episodes (UUI) are measured prospectively using 3- day voiding diaries administered at 
baseline, 4, 8, 12, 24, 36, and 48 weeks post -activation of the eCoinTM system.  
Change in Frequency: Frequency of urination is measured prospectively using 3- day 
voiding diaries administered at baseline, 4, 8, 12, 24, 36, and 48 weeks post -activation of 
the eCoinTM system.  
Change in Quality of Life: Quality of life is measured prospectively using the OABq 
questionnaires administered at baseline, 4, 8, 12, 24, 36, and 48 weeks post -activation 
of the eCoinTM system.  
Patient Global Impression of Improvement : The level of patient satisfaction with the 
eCoinTM neuromodulation system will be rated by the subject on a descriptive scale of 
very much worse, much worse, worse, about the same, better, much better, and very 
much better.  
Patient Reported Satisfaction : The level of patient satisfaction with the eCoinTM 
neuromodulation system will be rated by the subject on a scale of 1 to 5 where 1 is Not 
at All Satisfied, 2 is Slightly Satisfied, 3 is Somewhat Satisfied, 4 is Very Satisfied and 5 
is Completely Satisfie d. 
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 56 of 97   
  
3-9-6 Missing Outcome Data  
Because this study is investigating an implanted device, nearly all implanted patients are 
expected to have data on the primary and secondary endpoints.  Careful clinical 
planning that minimizes patient dropouts will be implemented.  
 
For the primary effectiveness outcome variable, missing data will be handled as follows:  
 
• Any subject explanted, except for those explanted for MRI, prior to 48 weeks 
post-activation will be imputed as a non -responder (meaning the subject will be 
imputed as having not achieved at least a 50% reduction from baseline in the 
number of urgency urinary incontinence episodes).  
 
• Subjects who are explanted for an MRI will have data post -MRI imputed. These 
imputed data for the primary effectiveness outcome variable will be assumed missing at random and will be handled with multiple imputation.  
 
• Any subject for whom 48 week post -activation data are unavailable and the study 
investigator does not know whether the device has been explanted will be assumed to be a  non-responder.  
 
• Subjects for whom 48 week post -activation data are unavailable but the device is 
known not to have been explanted will have their missing data imputed. The missing data for the primary effectiveness outcome variable will be assumed 
missing at random and will be handled with multiple imputation.  
 
• Any subject who undergoes the procedure for implantation of eCoinTM whether or 
not the device is actually activated, will be treated as if they were  activated.  
 
• An addendum to the SAP addresses missing data related to COVID -19 impact.  
 
Multiple imputation will be performed under fully conditional specification (FCS) with 100 imputed datasets. The model will include the following variables: sex, age, body mass 
index (BMI), response t o the TENS protocol, OABq total score at baseline and all follow - 
up visits, Patient Global Impression of Improvement questionnaire score at all post - 
baseline visits, average urinary voids per 24 hours on a 3- day voiding diary at baseline 
and all follow -up visits, and average UUI episodes per 24 hours on a 3- day voiding diary 
at baseline and all subsequent visits. The SAP will contain further details and SAS code 
concerning the modelling for multiple imputation.  
 
The SAP will provide further details on handling missing data for the secondary 
outcomes. For the analysis of safety variables, only partial dates may be imputed; 
otherwise, missing data will be treated simply as missing. Conventions for imputing 
partial dates will be described in the SAP.  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 57 of 97   
  
3-9-7 Sensitivity and additional analyses  
The primary and secondary efficacy analyses will be repeated for all analysis 
populations (mITT, OAB drug- free, Per -protocol, Responders, and TENS cohort 
analysis). These analyses will also be repeated fo r the mITT analysis population 
excluding any subjects enrolled but not meeting all eligibility criteria who were 
subsequently re- baselined to correct any eligibility violations.  
 
Additional sensitivity analyses may be conducted to evaluate different methods of handling missing data, such as tipping point, best -case, and worst -case scenario 
analyses.   Additional sensitivity analyses are described in the SAP addressing 
COVID -19 impact.  
 
3-9-7-1 Additional OAB medications  
Medications  for OAB are not allowed  until the primary  effectiveness  endpoint  is reached 
at 48 weeks post -activation, unless judged medically necessary. For the primary 
effectiveness outcome variable, the primary analysis will include all subjects who have 
taken OAB medications. OAB medication use will be reported alongside the primary 
analysis. The timing of OAB medications will be displayed, including duration of 
treatment, start and end dates, and dosage.  
 
The following additional sensitivity analyses may be performed.  
• For the primary effectiveness outcome variable at week 48, data for subjects who 
have taken OAB medications while on study will be considered missing and 
imputed assuming they had not taken any OAB  medication.  
• For weeks  4, 8, 12, 24, 36, and 48, 2 differen t sets of analyses  will be performed.  
o While  on OAB medication.  Subjects  will be imputed  as non-responders 
while they are taking OAB  medication.  
o Any OAB medication.  A very conservative  set of analyses  will consider  a 
subject  a non-responder  at every  visit after she starts  OAB  medication.  
 
For example, no matter what subjects write on their diaries, the “while on OAB 
medication” analyses will consider subjects as non- responders from week 12 through 
week 36 if they take OAB medication at week 12 and stop that medication at week 36. 
The “any OAB medication” analyses will consider such subjects non -responders from 
week 12 through week 48.  
 
3-9-8 Safety Analysis 
All AEs will be coded using the preferred terms described in Subsection 3 -7-4 Additional  
Safety Profile Information . All AEs will be summarized by preferred term. Tabulations of 
general AEs, which will be provided by time point, will include the number of subjects 
exposed, the number of subjects with at least one AE, and the number of subjects with 
at least one AE by preferred term. These tabulations will be repeated for all AEs 
recorded as having a causal relationship to the eCoinTM system. Tabulations of local AEs 
will be provided at 24 and 48 weeks after activation (28 and 52 weeks after 
implantation), and will inclu de the number of subjects exposed, the number of subjects 
with at least one AE, and the number of subjects with at least one AE by preferred term. Separate tables will be provided, if relevant, for SAEs or events leading to withdrawal 
from study.  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 58 of 97   
  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 59 of 97   
  
Data Handling, Record Keeping and Study Monitoring 
3-10-1 Confidentiality and Security  
The Investigator will ensure that the subject’s confidentiality is maintained on the CRFs 
or other documents submitted to the Sponsor. Subjects should be identified by their 
initials and a subject study number only. Documents that are not for submission to the 
Sponsor, such as the signed informed consent forms, should be kept in strict confidence 
by the Investigator. In compliance with ICH GCP Gui delines, the Investigator and 
institution are required to permit authorized representatives of the company, of any 
relevant regulatory agency, and the IRB direct access to review the subject’s original 
medical records for verification of study -related proc edures and data. Direct access 
includes examining, analyzing, verifying, and reproducing any records and reports that are important to the evaluation of the study. The Investigator will inform and obtain the consent of the subject to permit named represent atives to have access to his/her study - 
related records without violating the confidentiality of the subject. Information about study subjects will be kept confidential and managed according to the requirements of 
the clinical sites regulatory authority. A s a part of the consent process, subjects will sign 
an authorization informing the following:  
• What protected health information (PHI) will be collected from subjects in this  study  
• Who will have access to that information and why 
• Who will use or disclose that  information 
• What rights does a research subject have to revoke their authorization for use of 
their PHI 
3-10-2 Training 
All study forms and procedures will be reviewed with medical/study staff at the 
participating centers. Investigators or their surgical designees will also be medically 
trained and certified by the Sponsor to perform the implant procedure. Training will 
include any combination of cadaver training, video, or supervised procedures. To 
perform the procedure, the Investigator or designated medical doctor will need to be 
experienced in urology or uro- gynecology, and be certified by the Sponsor.  
3-10-3 Documentation, Case Report Forms and Source Documents 
All documents will be signed off by the Sponsor and controlled such that any revisions 
are approved and tracked, with each document identified with a document number  and 
revision code. Investigators will maintain the following items of documentation in the 
Investigator’s Study File on site: 
• Protocol and any  amendments  
• Consent forms (sample, and subject signed and  dated)  
• IRB/ERC approval for the protocol and consent  form 
• Agreement letter sent to Sponsor  
• Case Report Forms  
• Adverse event or Problem reports to Sponsor and IRB 
• Inventory control  log 
• Enrollment  Log 
• Records of deviations, violations, and amendments  
• Implant Registration Cards, where required by local  regulations  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 60 of 97   
  
Case Report Forms: All data requested on the CRF must be recorded. All missing data 
must be explained. If a space on the CRF is left blank because the procedure was not 
completed or the question was not asked, select “N/D”.  If the item is not applicable to 
the individual case, select “N/A”. If any entry  error has been made, to correct such an 
error, draw a single straight line through the incorrect entry and enter the correct data above it. All such changes must be initialed and dated. DO NOT ERASE OR WHITE 
OUT ERRORS. Case Report Forms will be kept in t he Study  File. 
Source Documents: medical records, voiding diaries, QoL questionnaires, etc. will be maintained at the study clinic.  
3-10-4 Device  Accountability 
Each device has a unique serial number assigned. The device box will have 2 adhesive 
labels with the s erial number of the device. At the time of implantation, one sticker will 
be placed on the Implantation CRF and the other sticker will be placed on the patient 
implantation card (see 4-7). The Sponsor is responsible for managing the device 
accountability log across the study. Each site will have a device tracker to be reconciled 
at the conclusion of the  study.  
3-10-5 Monitoring Procedures, Auditing, and Inspecting  
A clinical research monitor will supervise conduct of the study at each site in 
accordance with the Clinical Monitoring Plan provided in Attachment 4 -22. The monitor 
will visit the Investigator and the study facility at periodic intervals in addition to maintain 
ongoing telephone, e- mail, and letter contact. The monitor will maintain up- to-date 
personal knowledge of the study through observation, review of study records and 
source documentation, and discussion of the study wit h the Investigator and study 
personnel. The study site will assist the monitor by providing access to all relevant 
study  materials.  
The clinical monitors will be qualified members of the Clinical Research Department of 
Valencia Technologies who have been t rained on the study protocol, monitoring 
procedures, and standard operating procedures based on Good Clinical Practice and 
other applicable Federal regulations.  
The monitor’s responsibilities are:  
• Conduct Site Initiation visit (after IRB approval/before fi rst subject  enrollment).  
• Conduct periodic monitoring visits.  
• Compare case report forms to source  documents.  
• Review Investigator’s files for accuracy, currency, and completeness.  
• Ensure that informed consents are obtained.  
• Ensure that IRB review is  current.  
• Ensure protocol compliance; document  deviations.  
• Prepare reports of  visits.  
• Ensure adverse events are reported.  
• Conduct closeout visit (after all case report forms are received in house).  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 61 of 97   
  
3-10-6 Protocol Deviations and Compliance  
3-10-6-1 Major Pro tocol Deviations  
A major protocol deviation is defined as one that affects the safety of the subject or the 
scientific validity of the results.  
1) A Physician Investigator may deviate from the protocol in an emergency 
situation, such as when a departure from the protocol is required to protect the 
life or physical well- being of a participant. The Sponsor and the IRB/Ethics 
Committee must be notified as soon as possible, but not later than 5 days after the emergency situation occurred.  
2) Any non-emergency, major deviation to the protocol must be approved by the 
Sponsor and the IRB/Ethics Committee prior to implementation. If a major deviation occurs that is not in response to the protection of a subject, the event  is 
considered non -compliance if it occurs without prior approval. Non- compliance 
must be reported to the IRB/Ethics Committee promptly –  no later than 5 days 
after the deviation. A PI’s failure to report promptly any major deviation for which 
the PI did not obtain prior approval is it self an incident of non -compliance and will 
be evaluated by the Sponsor. Such failure could be grounds for physician disqualification.  
Use of a medication for OAB is not considered a major protocol deviation.  
3-10-6-2 Minor or Administrative Protocol  Deviations 
A minor deviation is defined as one that does not affect the safety of the subject or the 
scientific validity of the results. Minor deviations from the protocol should be noted on the 
protocol deviation log at the site and brought to the attention of the moni tor at the next 
CRA visit. These deviations do not need to be reported to the IRB/Ethics Committee.  
Examples of a minor protocol deviation follow:  
1) Follow -up visits that occurred outside the protocol required time frame  because 
of the participant’s  schedule.  
2) Study procedure conducted out of timeframe, e.g., 3- day diary  
3) Participant failure to initial every page of the consent  form 
4) Participant failure to return patient  diary  
5) Copy of the ICF not given to the  participant  
6) Missing original signed consent, but a copy  exists  
7) Patient not given implant card  
8) Use of a medication for  OAB 
3-10-6-3 Analyzing Deviations  
At each monitoring visit, the deviations log will be reviewed along with any additional 
deviations that might be discovered during the monitoring visit. If any minor deviation is 
deemed to have an impact on the trial outcomes, the issue must be brought to the attention of the Sponsor.  
3-10-6-4 Statement of Clinical  Compliance  
The study will be conducted in accordance with the design and specific provisions of this 
IRB/Eth ics Committee approved protocol, in accordance with the ethical principles that 
have their origin in the Declaration of Helsinki, and that are consistent with Good Clinical 
Practice (GCP) and applicable regulatory requirements. The Investigator will assure that 
no deviation from, or change to, the protocol will take place without prior agreement from  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 62 of 97   
  
the Sponsor and documented approval from the IRB/Ethics Committee, except where 
necessary to eliminate an immediate hazard to the trial participants. The Investigator will 
promptly report to the IRB/Ethics Committee and the Sponsor any changes in research 
activity and all unanticipated problems involving risk to human subjects, or others.  
 
Methods, Facilities, and Control Information 
3-11-1 Device  Manufacturer 
3-11-1-1 Manufacturer name, address and contact  information 
Name of device manufacturer: Valencia Technologies Corporation  
Address: 28464 Westinghouse Place, Valencia, CA 91355 
Contact Person: Stacy Chambliss, Chief of Administration 
Telephone Number: (661) 775 -1414  
Fax Number: (661) 775- 1411 
3-11-1-2 Manufacturer compliance with Subpart C, Design Controls 
(section 820.30), the Quality System Regulations (21 CFR Part  820) 
The eCoinTM Subcutaneous Neuromodulation System is manufactured by Valencia 
Technologies Corporation under design controls per QSR 21 820.30 and ISO 13485.  
3-11-1-3 Device Design and Manufacturing  Information 
Device Design  
Engineering drawings of the eCoinTM Subcutaneous Neuromodulation System described 
in section 3-8 are in attachment 4-19. Materials used outside of the hermetic package in 
the eCoinTM device are in attachment 4 -20. 
Design inputs for the eCoinTM Subcutaneous Neuromodulation System  include the 
requirements for functional performance and safety including applicable regulatory and 
legal requirements as well as the outputs of risk management. The design outputs for 
the eCoinTM Subcutaneous Neuromodulation System are captured in functional 
specification requirements. These design outputs are verified in the testing summarized 
in Attachment 4 -16 using test articles that are representative of the final product. The 
clinical use of the eCoinTM device has been validated in a successful first in human 
feasibility trial from 2013 through 2016 for the treatment of drug resistant hypertension in 
adults per the protocol in Attachment 4 -11. Subsequent to this trial and more relevant to 
the protocol described herein, the clinical use of eCoinTM in the treatment of OAB with 
urge urinary incontinence has been validated in a feasibility trial and the protocol is attached as Attachment  4-33
. 
Design Reviews are conducted with representatives of functions concerned with t he 
design and development stage being reviewed. Other specialist personnel are included 
as needed. Design changes arising from these reviews are verified and validated before 
approval and release.  
3-11-1-4 Manufacturing Controls  
Assembly procedures with test procedures are in place to ensure the eCoinTM device is 
produced in accordance with the design and performance specifications (attachment 4 - 

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 63 of 97   
  
23). Each device is tracked individually by serial number with traceability to components 
and all production steps maintained in a device history record.  
3-11-1-5 Processing, Packaging,  Storage  
The procedures for sterile packaging, sterilization and storage are in Attachment 4 -24. 
Study Sites and Investigators  
3-11-2 Organization and Participating  Center 
3-11-2-1 Principal  Investigators  
All U.S. based Principal Investigato rs participating in the study will have signed an  
Investigator Agreement, a template of which is enclosed as Attachment 4 -21 in 
compliance with § 812.43. New U.S. based Principal Investigators will be required to 
sign the Inv estigator Agreement before being added to the study. Attachment 4 -25 is the 
list of 20 investigators and centers.  
 
Sponsor  
Valencia Technologies Corporation 
Stacy Chambliss, Tel: +1 (661)775- 1414 ext. 1002 
28464 Westinghouse Place 
Valencia CA, 91355 
United States  
3-11-3 Funding Source and Conflicts of  Interest 
The study is funded by Valencia Technologies. Participating centers will be paid according to clinical trial agreements. Participating physicians have disclosed their 
financial relationship in the Conflict of Interest statement incorporated within the signed 
Investigator Agreement,  
3-11-4 Institutional Review Board / Ethics Committees  
Institutional Review Board / Ethics Committees will approve the protocol for each 
respective center pursuant to center requirements or under an independent review 
board.  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 64 of 97   
  
3-11-5 Roles and Responsibilities  
3-11-5-1 Investigator  
The Investigator has the following responsibilities:  
1) Assure IRB/Ethics Committee approval of protocol and informed consent is 
obtained.  
2) Follow the study  protocol.  
3) Permit monitor to inspect facilities and records.  
4) Permit regulatory inspections of facilities and records, if  necessary.  
5) Inform a patient of any known risks and potential benefits associated with use of 
the device, and obtain the patient’s written consent for its  use. 
6) Enroll subjects, execute study, and transcribe data from source documents to 
Case Report  Forms.  
7) Submit annual progress reports, final reports, and adverse event reports to the 
IRB/Eth ics Committee and to the  Sponsor.  
8) Return unused study articles, record their receipt, disposition, and  return.  
9) Refrain from promoting study or study articles in any manner that is not 
authorized by the Sponsor.  
10) Conduct study in accordance with the protocol.  
11) Track Sponsor -provided inventory and  assignments.  
12) Maintain medical histories of  subjects.  
13) Retain records for 10 years or as required by law following completion of the 
study.  
3-11-5-2 IRB/Ethics Committee  
The following are the responsibilities of the IRB:  
1) Review and approve, modify, or disapprove the study protocol and informed 
consent  form.  
2) Receive continuing and final reports on study  progress.  
3-11-5-3 Sponsor  
The Sponsor has the following responsibilities:  
1) Submit protocol and informed consent to IRB/Ethics Committee and FDA and await approval before starting the study.  
2) Submit proposed amendments to the protocol and informed consent to 
IRB/Ethics Committee and Regulatory Authority (where applicable and  await 
approval, unless the change reduces the risk to  subjects).  
3) Assure IRB/Ethics Committee and Regulatory Approval (where applicable) is 
obtained.  
4) Select and train  monitors.  
5) Select and train Investigators and study  personnel.  
6) Obtain agreement letter and c.v. of each Investigator.  
7) Control shipment of  devices and surgical  tools.  
8) Conduct overall administration of  study.  
9) Investigate unanticipated, device -related adverse events.  
10) Document protocol deviations and violations.  
11) Report and respond to the DSMB.  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 65 of 97   
  
3-11-5-4 DSMB  
1) The responsibilities of the DSMB are outlined in the DSMB Charter (see 
Attachment  4-10).  
3-11-6  Subject Compensation  
Subjects will not be paid for participation in this study. However, they will be provided a 
small stipend for travel and accommodation expenses associated with the study 
treatment and follow -up requirements.  
 
Study Timetable  
Study initiation is planned for July 2018. Study enrollment of up to 135 subjects is 
expected to be completed by March 2019. All subjects are expected to complete the 
study  by April 2020. Monitoring is expected to be completed by June 2020.  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 66 of 97   
  
 
 
4 Attachments  
Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 67 of 97   
  
3-day Voiding Diary  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 68 of 97   
  
Manuals, and Labels 

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 69 of 97   
  
Investigator’s Brochure  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 70 of 97   
  
Patient Trial Brochure and Advertisement  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 71 of 97   
  
Informed Consent Document  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 72 of 97   
  
Patient Global Impression of Improvement  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 73 of 97   
  
Patient Implantation Card  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 74 of 97   
  
Case Report Forms  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 75 of 97   
  
Adverse Event Form  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 76 of 97   
  
DSMB Charter 

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 77 of 97   
  
OUS Study for Hypertension Protocol  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 78 of 97   
  
OUS Study for Hypertension CRFs for Infections  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 79 of 97   
  
OUS Study for Hypertension DSMB Letter Recommending 
Suspension of Implantation at Site 12  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 80 of 97   
  
SNS Ri sk Assessment (110 -1493)  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 81 of 97   
  
Summary of Risks and Mitigations  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 82 of 97   
  
Design Verification and Validation Reports  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 83 of 97   
  
Ethylene Oxide Sterilization Validation Reports  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 84 of 97   
  
Sterile Packaging Validation Report  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 85 of 97   
  
Engineering Drawings  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 86 of 97   
  
eCoinTM Device Materials  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 87 of 97   
  
Template Investigator Agreement  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 88 of 97   
  
Clinical Monitoring Plan 

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 89 of 97   
  
Assembly Procedure eCoinTM Device  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 90 of 97   
  
Assembly Procedure Ste rilization and Packaging Clinical 
Monitoring Plan 

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 91 of 97   
  
List of Investigators, CVs, and Centers  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 92 of 97   
  
303-1122 Software Design Specification SNS 

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 93 of 97   
  
Biocompatibility Reports  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 94 of 97   
  
Bacterial Endotoxins Test Method 

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 95 of 97   
  
Bioburden Levels and Raw Data  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 96 of 97   
  
Battery Receiving Inspection Instructions 

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 97 of 97   
  
References  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 98 of 97   
 eCoinTM for OAB Feasibility: Safety  
4-32-1 Adverse Event Table 
4-32-2 Subject 01-10 One Month Follow-up Implant Site  Picture 
4-32-3 Subject 07- 17 AE  report  

Original Application for an Investigational Device Exemption  
Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for Urgency Urinary 
Incontinence.  
Valencia Technologies Corporation 
CONFIDENTIAL  Doc. No. 111-3281  Rev 3.9 
Page 99 of 97   
 eCoinTM for OAB Feasibility Study Protocol  
